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In this project two medicinal plant species, namely Hypoxis colchicifolia Bak (Hypoxidaceae) 
and Terminalia sericea Burch. (Combretaceae), have been investigated and different 
compounds isolated and characterised. The aim of this study was to investigate the 
phytochemistry and antidiabetic activity of H. colchicifolia and T. sericea. 
H. colchicifolia (H. latifolia) is after H. hemerocallidea (African Potato) the second most 
important Hypoxis medicinal species with commercial value in South Africa. From the 
methanol extract of the corms, four phenolic derivatives, hypoxoside, a mixture of 
dehydroxyhypoxoside A and B and bis-dehydroxyhypoxoside were isolated, as well as an 
environmental impurity bisphenol A diglycidyl ether. This is the first study on the isolation of 
the dehydroxyhypoxoside B. The methanol extract of H. colchicifolia showed glucose 
lowering effects and low toxicity in vitro against C2C12 muscle cells and Chang liver cells. 
Of the pure compounds, only the mixture of dehydroxyhypoxoside A and B showed an 
increase in glucose utilization by the muscle cell line C2C12. 
T. sericea is an important plant in traditional medicine and is in the top 50 most important 
African medicinal plants. From the methanol extract of the roots, one known compound, 
sericic acid, was isolated. The methanol extract of T. sericea roots showed an increase in 
glucose utilization by C2C12 muscle cells and Chang liver cells but the extract also showed 
some cytotoxicity towards these cells. 
Structural elucidation of the different compounds was achieved by using NMR spectroscopy 
in one and two dimensions, high-resolution mass spectrometry, infrared spectroscopy and 
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CHAPTER 1: INTRODUCTION 
 
1.1 PLANTS AS A SOURCE OF MEDICINAL COMPOUNDS 
Natural products were the basis of ancient systems of traditional medicine, such as the 
Chinese, Ayurvedic and Egyptian systems (3000 BC) (Doughari  and Rao, 2012; Sarker et al., 
2006). Sarker et al. (2006) give (in their book Natural Products Isolation) a brief history on 
the evolution of medicinal natural products: 
- Ebers Papyrus (1550 BC) listed a series of crude drugs from natural sources (e.g. castor 
seeds and gum arabic). 
- Hippocrates (450 - 377 BC), Theophrastus (370 - 287 BC) and Pliny (23 - 79 AD) 
described several plants and animals that could be used in medicine. 
- Dioscorides (60-80 AD) presented in his book De Materia Medica a description of over 
600 medicinal plants. 
- Galen (131-200 AD) practiced botanical medicines (Galenicals) and made it popular in 
Europe. 
- Kraüterbuch (15th century) presented information and pictures of medicinal plants. 
According to the World Health Organization (WHO, 2003) about 80% of people in 
developing countries rely on traditional plant-based medicines for their primary health care. In 
1998 it was estimated that the commercial value of ethnomedicinal plants traded in the 
province of Kwazulu-Natal in South Africa was R60 million. In addition, most households, 
especially in the rural areas, spend between 4 and 8% of their annual income on traditional 
medicinal services (Mulholland and Drewes, 2004). 
In most plants, the active compounds are secondary metabolites. Secondary metabolites are 
defined as small molecules (molecular weight <2000 amu) produced by an organism that are   
not strictly necessary for the survival of the organism. These compounds  are responsible for 
protecting plants against microbial infections or infestations by pests (Doughari  and Rao, 
2012; Sarker et al., 2006). These secondary metabolites are often referred to as natural 
products. Natural products isolated from plants and microorganisms have played a vital role 
as a source of lead compounds for the pharmaceutical industry.  
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The isolation of active compounds from plants started early in the nineteenth century when 
compounds such quinine (1.1) were obtained as pure compounds. Quinine (1.1) is an 
antimalarial compound that was isolated from the bark of the Cinchona tree by the French 






1.1 Quinine   
The Indian subcontinent is a good example of an extensive indigenous pharmacopoeia, 
including the Ayurvedic, Unani, and folkloric medical systems, which has already supplied 
drugs such as reserpine (1.2) (antihypertensive and tranquilizer), from Rauvolfia serpentina. 
Reserpine is also reported to be hypoglycaemic in normal animals (Marles and Farnsworth, 
1995). 














1.2 Reserpine   
In the last century a series of important medicines were developed from natural products such 
as morphine (1.3) (analgesic) from Papaver somniferum, vincristine (1.4) (anticancer drug) 
from Vinca rosea and Taxol® (1.5) (anticancer drug) from Taxus brevifolia (Sarker et al., 







1.3 Morphine  
 









































It is estimated that 40% of modern drugs in use have been developed from natural products 
(Sarker et al., 2006). More specifically, 39% of the 520 new drugs approved between 1983 
and 1994 were natural products or their derivatives and 60–80% of the antibacterial and 
anticancer drugs were from natural origins (Newman et al., 2003). 
From the 1940s to 2012, of the 175 small molecules used to treat cancer, 47% were natural 
products or directly derived from natural products (Newman and Cragg, 2012). Eight of the 
30 top-selling medicines in 2001, namely simvastatin (1.6) (synthetic derivative of a 
fermentation product of Aspergillus terreus), pravastatin (1.7)  (a derivative of a fungal 
metabolite from Penicillium citrinum), amoxicillin (1.8), clavulanic acid (1.9) (produced by 
Streptomyces clavuligerus), azithromycin (1.10), ceftriaxone (1.11), cyclosporin (1.12) 
(isolated from the fungus Tolypocladium inflatum (Beauveria nivea) and Taxol® (1.5) 
(isolated from the bark of Taxus brevifolia) were natural products or their derivatives, 
together totaling US $16 billion in sales (Newman and Cragg, 2012; Newman et al., 2003; 
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1.11 Ceftriaxone  
 
Figure 1.1: Anti-cancer drugs. 
 
It is estimated that the terrestrial flora consist of between 300000 to 500000 species of higher 
plants. However, in terms of pharmacological and phytochemical research, it is estimated that 
only 6% and 15% of the species, respectively, have been investigated. 
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1.2 DIABETES AND MEDICINAL PLANTS 
Diabetes is a major health problem worldwide. Many Southern Africa medicinal plants are 
used for treatment of diabetes, as will be discussed in Chapter 2. Our hypothesis is that many 
of the plants that are used by people do have antidiabetic activity and that specific compounds 
with antidiabetic activity can be isolated from these plants. The aim of this investigation was 
to investigate the activity and phytochemistry of two plants that are used by people as a 
treatment for diabetes. 
The specific objectives of this project were the:  
- Isolation of the secondary metabolites from H. colchicifolia. 
- Structure elucidation of the compounds isolated from H. colchicifolia. 
- Antidiabetic activity of the MeOH extract and the isolated compounds from H. 
colchicifolia and Terminalia sericea. 
- Structure elucidation of isolated compounds from T. sericea. 
The structure of the rest of the thesis is as follows: 
Chapter 2 is a literature review on diabetes, drugs used during treatment and medicinal plants 
used in South Africa for the treatment of this disease. Chapter 3 gives a brief discussion of the 
Hypoxidaceae and the phytochemistry of the species of this family. The isolation, 
purification, identification, and anti-diabetic activity of the MeOH extract and compounds 
isolated from Hypoxis colchicifolia are described. In Chapter 4 the anti-diabetic activity of the 
MeOH extract from Terminalia sericea and the isolation, purification and identification of a 
compound are discussed. 
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The International Diabetes Foundation (IDF) define diabetes mellitus, or only diabetes, as “a 
chronic disease when the pancreas is no longer able to make insulin, or when the body cannot 
make good use of the insulin it produces’’(IDF, 2008).  Carbohydrates in food are broken 
down to glucose in the blood. Insulin, a peptide produced by the beta cells in the pancreas, 
assists in the uptake of glucose by the cells either for energy or to store it for future uses. 
Insulin helps in controlling blood glucose levels from being too high (hyperglycaemia) or too 
low (hypoglycaemia). Over time, high glucose levels in the blood adversely affect a person’s 
health as a result of damage to the heart and blood vessels, kidneys, eyes and nerves. 
There are two main types of diabetes: 
Type 1 diabetes (insulin-dependent diabetes): Usually as a result of an auto-immune disease, 
the pancreas is producing very little or no insulin. The disease normally develops in children 
or young people and is treated by insulin injections.  
Type 2 diabetes (non-insulin dependent type diabetes): The body produces enough insulin, 
but the cells do not utilize it properly. It accounts for about 90% of all cases of diabetes and is 
closely associated with obesity and lack of exercise.  
It is estimated that there are currently 387 million people (8% of the world’s population) 
living with diabetes (half of them undiagnosed) and that this number will increase to 592 
million in the next 20 years (IDF, 2008). Diabetes is also a risk factor for active tuberculosis 
and the reactivation of latent tuberculosis (Leow et al., 2014). The probability of type 1 
diabetics to become sick from latent tuberculosis is much higher than that of non-diabetic 
patients because their immune systems are compromised. In South Africa, the prevalence of 
diabetes is 8% and according to the most recent report of Stats SA, it is the 5th most important 
cause of death in South Africa (Witness, 2014). The increase in type 2 diabetes in developing 
countries, including Africa, is directly associated with inadequate nutrition, obesity and 
physical inactivity. 
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 2.2 DRUGS USED FOR THE TREATMENT OF DIABETES 
The available anti-diabetic drugs can be classified according to their mechanisms (Kemp, 
2012; Patel et al., 2012) as summarized in Table 2.1. 
Table 2.1: Major drug classes approved for treatment of hyperglycaemia in patients with 
type 2 diabetes (Kemp, 2012). 
 











GPLP-1 receptor  
DPP4/ GLPI 
Insulin secretion 
Hepatic glucose output 
Insulin sensitization 




The sulfonylureas (Figure 2.1) were the first generation of approved antidiabetic drugs 
developed in 1955, the second-generation sulfonylureas (currently in use) were introduced in 
1984 (Kemp, 2012). Even though the first generation drug chlorpropamide (2.1) causes side 
effects more frequently, the incidence of severe hypoglycaemia is high with the second 
generation glyburide (2.2). To correct this problem, Gliclazide® (2.3) was developed (Marles 
and Farnsworth, 1995). 
None of the sulfonylureas (first and second generation) currently in use completely 
normalized insulin secretion. The lack of response to sulfonylureas may be primary (25% - 
30% of treated patients) or secondary, occurring in 5% - 10% of patients per year. The side 
effects of sulfonylureas are hyponatremia, hepatitis, hematological reactions and 
dermatological effects (Marles and Farnsworth, 1995). 




































































Figure 2.1: Sulfonylurea drugs used for type 2 diabetes. 
 
2.2.2 Metformin                                                       
Metformin (2.4) is a natural product that was first isolated from Galega officinalis (Dunn and 
Peters, 1995; Witters, 2001). The drug, which was introduced to the market in 1995, is a less 
toxic biguanides and a potent oral glucose-lowering agent and is the only drug approved to 
treat diabetes in children (Patel et al., 2012). It is also particularly effective for treatment of 
overweight and obese people. Metformin (2.4) acts by suppression of glucose production by 
the liver (Kemp, 2012). Metformin (2.4) is used for cases of diabetic patients with 
cardiovascular complication and reduced levels of cholesterol and triglycerides, and has a 
neutral effect on individuals with normal weight (Kemp, 2012). Metformin (2.4) has side 
effects with the most common adverse effect being gastrointestinal upset. Lactic acidosis can 
also be a serious problem,  particularly in cases of individuals with contra-indications (Kemp, 
2012). 








2.4 Metformin  
2.2.3 Thiazolidinediones 
Thiazolidinediones (glitazones) (Figure 2.2) was introduced in 1999. Some of the 
thiazolidinediones are known for their adverse effects, for example pioglitazone (2.5) was 
suspended from sale in France and Germany due to an increased risk of cardiovascular events 
and troglitazone (2.6) was withdrawn from the market because of the increasing incidence of 
drug-induced hepatitis (Bernstein, 2012). Because of this, the FDA recommends observation 
of liver enzymes in the first year of therapy with thiazolidinediones in order to verify possible 










































 Ciglitazone  





Figure 2.2: Thiazolidinedione drugs used for type 2 diabetes.  
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2.2.4 Acarbose 
Acarbose (2.7) is obtained by biotechnology from filtered fungi known as Actinomycetes. It is 
an inhibitor of the enzyme α-glycosidase and is indicated in the treatment of diabetes mellitus 
type 2 and also type 1 in combination with insulin (Fowler, 2007). It has side effects such as 
hernias, excessive flatulence and is not recommended for pregnant women, lactation, and 





















2.7 Acarbose  
2.2.5 Incretin mimetics 
This type of drugs acts by increasing the levels of the incretins, a group of gastrointestinal 
hormones. In the body, these hormones help to produce more insulin when needed and reduce 
the amount of glucose being produced by the liver when it is not needed (Wilcox, 2005). It 
also controls the rate at which the stomach digests food and empties, and appetite. Currently, 
there are three types of incretin drugs; exenatide (2.8), liraglutide (2.9) and lixisenstide (2.10).  
Exenatide (2.8), a 39-amino-acid peptide which was approved by the FDA in 2005, is a 
synthetic version of exendin-4, a hormone found in the saliva of the Gila monster (Kim and 
Egan, 2008). Exenatide (2.8) affects the gastrointestinal system and side effects include acid 
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Liraglutide 2.9 was approved by the FDA in 2010 and may have advantages over current 
therapies. It acts in a glucose-dependent manner; consequently, it shows lower risk of 
hypoglycaemia. It can inhibit apoptosis, stimulate the regeneration of beta cells, reduce 
appetite and assist in maintaining body weight. It also lowers blood triglyceride levels (Kim 









C-16 fatty acid (palmitoyl)
2.9 Liraglutide  
Lixisenatixe (2.10) is derived from the first 39 amino acids in the sequence of the peptide 
exendin-4, found in the Gila monster (Heloderma suspectum) and was approved by the FDA 





2.2.6 Dipeptidyl peptidase 4 (DPP4) inhibitors 
DPP4 inhibitors, known as gliptins, are a new class of oral medication used to treat diabetes 
mellitus type 2 (Figure 2.3). They were introduced onto the market in 2006 and the first drug 
of this class approved by the FDA was Sitagliptin® (2.11) (Pei, 2012). Side effects such as 
nasopharyngitis, heart failure, headache, nausea, hypersensitivity and skin reactions have been 
observed in clinical studies (Cummins, 2012). Although not fully confirmed, there are claims 
that DPP4 inhibitors increase the risk of pancreas cancer (Nauck and Friedrich, 2013). The 
natural compounds berberine (2.12), belonging to the protoberberine group of isoquinoline 
alkaloids, and lupeol (2.13), a triterpene found in many plants, are also DPP4 inhibitors (Al-
masri et al., 2009; Saleem et al., 2014). 
































































 Alogliptin               
Figure 2.3: DPP4 inhibitor drugs used for type 2 diabetes.      
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2.3 MEDICINAL PLANTS USED FOR TREATMENT OF DIABETES  
To ascertain whether medicinal plants are used for the treatment of diabetes mellitus, the 
treatment of symptoms of pronounced thirst and polyuria should be considered. In the 
ethnopharmacological literature, the use of more than 1200 species of organisms to treat 
symptoms of diabetes have been reported. This represents more than 725 genera in 183 
families, extending from marine algae and fungi to advanced plants. Eight hundred plant 
species may have anti-diabetic potential (Marles and Farnsworth, 1995; Patel et al., 2012). In 
Table 2.2, the plant families most frequently cited are summarized. 
Table 2.2:  Plant families most frequently cited for antidiabetic activity (Marles and 
Farnsworth, 1995). 
 
Family Species Cited Total of Species  
Fabaceae 127 18000 
Asteraceae 98 21300 
Liliaceae 35 6460 
Poaceae 30 10000 
Euphorbiaceae 30 7000 
2.3.1 Medicinal plants used to treat diabetes in South Africa  
Plants used in South Africa to treat diabetes have been reviewed by Deutschländer et al., 
(2009), van der Vender (2008) and Afolayan (2009). Ethnobotanical surveys of plants used 
for diabetes were recorded by Erastus (2005, Eastern Cape) and Semenya (2012, Limpopo). A 
summary of these studies are collated in Table 2.3. 
Table 2.3: Plants used for diabetes in South Africa. 
 
Family Scientific name/ Part used References 
Amaryllidaceae Gethyllis namaquensis (bulb) (Semenya et al., 2012) 
Anacardiaceae  Lannea edulis (bark of the woody 
underground rootstock) 
Sclerocarya birrea (roots, bark,and 
leaves) 
(Deutschländer et al., 2009) 
 
(van de Venter et al., 2008) 
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Apiaceae Centella asiatica (roots) 
Heteromorpha arborescens (leaves 
and roots) 
Petroselenium crispum (roots) 
(Semenya et al., 2012) 
(Erasto, 2005) 
 
(Thring and Weitz, 2006) 
Apocynaceae Catharanthus roseus (leaves, flowers  
and twigs) 
Hoodia currorii (fleshy stem) 
Plumeria obtusa (leaves) 
Vinca major (stems)  
(Erasto, 2005; van de Venter et 
al., 2008) 
(Von Koenen, 2001) 
(Semenya et al., 2012) 
(van de Venter et al., 2008) 
Araliaceae Cussonia spicata (roots) (Semenya et al., 2012) 
Asphodelaceae Aloe ferox (leaves) 
Bulbine natalensis  (roots) 
Bulbine frutescens (roots) 
Bulbine latifolia (fresh leaves and 
roots) 
Aloe marlothii (leaves and roots) 
(Deutschländer et al., 2009) 
(Erasto, 2005) 
(Erasto, 2005) 
(Van Wyk et al., 2005) 
 
(Semenya et al., 2012) 
Asteraceae Artemisia afra (leaves an roots) 
Brachylaena discolor (leaves) 
 
Brachylaena elliptica  (leaves) 
 
Brachylaena ilicifolia  (leaves) 
Callilepis laureola (roots) 
Cnicus benedictus  (leaves) 
 
Conyza scabrida (leaves) 
Elytropappus rhinocerotis (leaves) 
Helichrysum caespititium (whole 
plant) 
Helichrysum nudifolium (leaves and 
roots) 
 
Helichrysum odoratissimum (whole 
(Erasto, 2005) 
(Erasto, 2005; van de Venter et 
al., 2008) 
(Watt and Breyer-Brandwijk, 
1962) 
(Coates Palgrave, 1984) 
(Semenya et al., 2012) 
(Watt and Breyer-Brandwijk, 
1962) 
(Thring and Weitz, 2006) 
(Thring and Weitz, 2006) 
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plant) 
Helichrysum petiolare (whole plant) 
Pteronia divaricata  (whole plant) 
Schkuhria pinnata (whole plant) 
Tarchonanthus camphoratus (roots) 
Vernonia amygdalina (leaves) 




(Deutschländer et al., 2009) 
(Taylor, 2006) 
(Semenya et al., 2012) 
(Erasto, 2005) 
(Erasto, 2005) 
Buddlejaceae Chilianthus olearaceus (leaves and 
twigs) 
(Erasto, 2005) 
Cactaceae Opuntia ficus-indica  (roots) (Semenya et al., 2012) 
Cannabaceae Cannabis sativa  (leaves) (van de Venter et al., 2008) 
Canellaceae Warburgia salutaris (stem bark) (Deutschländer et al., 2009) 
Caricaceae Carica papaya (roots) (Semenya et al., 2012) 
Celastraceae Catha edulis (leaves, stems and 
roots) 
Elaeodendron transvaalense (bark) 
(van de Venter et al., 2008) 
 
(Deutschländer et al., 2009) 
 
Combretaceae Terminalia sericea (stem bark and 
roots) 
(Nkobole, 2009) 
Cucurbitaceae Momordica balsamina (whole plant) 
Momordica charantia (leaves) 
Momordica foetida (whole plant) 
Kedrostis nana (underground 
tuber) 
(van de Venter et al., 2008) 
(Semenya et al., 2012) 
(van de Venter et al., 2008) 
(Deutschländer et al., 2009) 
Ebenaceae  Euclea undulata  (roots) 
Euclea natalensis (bark and roots) 
(Deutschländer et al., 2009) 
(Deutschländer et al., 2009) 
Euphorbiaceae Bridelia micrantha (stem bark) 
Ricinus communis (leaves) 
 
Spirostachys africanus (bark) 
(Deutschländer et al., 2009) 
(Thring and Weitz, 2006) 
(Chadwick et al., 2007; 




Sutherlandia frutescens (leaves and 
 
(Chadwick et al., 2007; 
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roots) MacKenzie et al., 2009) 
Gentianaceae Chironia baccifera (twigs) (MacKenzie et al., 2009) 
Hypoxidaceae Hypoxis hemerocallidea  (corms) 
 
Hypoxis colchicifolia (corms) 
Hypoxis iridifolia  (corms) 
(Erasto, 2005; Ojewole, 2006) 
(Erasto, 2005) 
(Semenya et al., 2012) 
Kirkiaceae Kirkia wilmsii (tuber) (Semenya et al., 2012) 
Lamiaceae Leonotis leonurus (leaves and 
flowers) 
(Thring and Weitz, 2006) 
Lauraceae  Persea americana (roots) (Semenya et al., 2012) 
Lythraceae Punica granatum (roots) (Semenya et al., 2012) 
Menispermaceae Cissampelos capensis (leaves) (van de Venter et al., 2008) 
Mesembryanthe
maceae 
Carpobrotus edulis (leaves) 
 
(Van Huyssteen, 2003) 
Moraceae Ficus carica  (roots) (Semenya et al., 2012) 
Moringaceae Moringa oleifera (seeds and leaves) (Semenya et al., 2012) 
Myrtaceae Psidium guajava (leaves and roots) 
Syzygium cordatum (leaves) 
(van de Venter et al., 2008) 
(Musabayane et al., 2005) 
 
Nymphaeaceae Nymphaea nouchali (seeds) 
 
Trigonella foenumgraecum (seeds) 
(Watt and Breyer-Brandwijk, 
1962) 
(Van Wyk B, 1997) 
Rhamnaceae Ziziphus mucronata (leaves) (Mushtaq et al., 2007) 
Rubiaceae Galium tomentosum (roots) (Van Wyk, 2008) 
Rutaceae Clausena anisata (roots) (Ojewole, 2002) 
Sapotaceae Mimusops zeyheri (leaves) 
Englerophytum magalismontanum 
(bark) 
(Semenya et al., 2012) 
(Semenya et al., 2012) 
Sterculiaceae Hermannia quartiniana (roots) (Semenya et al., 2012) 
Tiliaceae Triumffeta sp. (roots) (Semenya et al., 2012) 
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In the Table above, 73 plants used for diabetes in South Africa are listed. However, only a 
small proportion of these species have been investigated to confirm their antidiabetic activity. 
The plants subjected to in vitro and in vivo antidiabetic assays and their active compounds are 
collated in Table 2.7.  
 
Table 2.4: In vivo and in vitro studies on antidiabetic plants used in South Africa. 
 
Plant / Family Extract/ Part used Assay Activity of the 
compounds and extracts 
C. edulis 
(Celastraceae)       
(van de Venter et al., 
2008) 
Aqueous  (leaves) Murine cell 
line C2C12 
The extract showed high 
activity and low toxicity in 
C2C12 cell line. 
C. roseus 
(Apocynaceae)  













The compounds show 
activities, especially 
vindoline derivatives which 
have been clinically tested. 
H. hemerocallidea  
(Hypoxidaceae)  
(Ojewole, 2006) 
Aqueous (corms) Animal The plant extract (50–800 
mg/kg) significantly 
reduces   (P < 0.05–0.001) 
hypoglycaemia in normal 
(normoglycaemic) and 
diabetic rats. 
    





Aqueous  (leaves) Animal The extract cause 
significant hypoglycaemic 
effects in rats. 
M. foetida 
(Cucurbitaceae)    
(van de Venter et al., 
2008) 
Aqueous (fruits) Animal 
Human 
Foetidin, mixture 1:1 of β-
sitosterol glucoside (2.21) 
and  5,25-stigmasterol 
glucoside (2.22) (Figure 
2.5)                                
The extract showed 
activity, but also toxicity. 
M. chararantia  
(Raman and Lau, 
1996) 
Aqueous (fruits and 
seeds) 
Animal Foetidin (2.21) , Vicine 
(2.23) (Figure 2.5)          
The compounds have 
hypoglycaemic effects, but 
at high concentrations. 
P. guajava 
(Apocynaceae)      
(van de Venter et al., 
2008) 
Aqueous (leaves) Animal Ellagic acid (2.24) 
Guiajaverin (2.25) 
Quercitrin (2.26)       
(Figure 2.6)                     
The extract showed 
activity, but also toxicity in 
C2C12 cell line. 
Syzygium cordatum  
(Myrtaceae) 




Animal Oleanolic acid  (2.27)               
Ursolic acid (2.28)     
Methyl maslinate  (2.29 )            
Methyl corosolate (2.30) 
(Figure 2.7) 
The extract decreased 
plasma glucose in non-
diabetic and STZ-diabetic 
rats. The compounds could 
be effective in mild 
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diabetes mellitus or in 









The extract showed high 
activity and low toxicity in 
C2C12 cell line. 
S. frutescens 
(Fabaceae)(Chadwick 
et al., 2007) 
Aqueous (leaves) Animal The extract shows ability to 
normalize insulin levels 
and glucose uptake in 
peripheral tissues and 








































2.17 Vindoline        













2.20 Eburnamonine  







2.21 -Sitosterol glucoside      
 
Figure 2.5: Antidiabetic compounds from Momordica foetida and Momordica charantia.  
 






2.25 R= Guiajaverin:  L-arabinose                       
2.26 R= Quercitrin: L-rhamnose
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Figure 2.7: Antidiabetic compounds from Syzygium cordatum.    
 
2.4 CONCLUSION  
It can be concluded that despite the high number of plants used in traditional medicine, only a 
limited number of plants have been investigated. The validation of traditional knowledge 
through research on plants used in traditional medicine to treat diabetes can be an effective 
strategy in combating this disease particularly in Africa where the high cost of drugs available 
in the market is problematic. 
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CHAPTER 3: A PHYTOCHEMICAL AND ANTIDIABETIC 
INVESTIGATION OF HYPOXIS COLCHICIFOLIA 
 
3.1 INTRODUCTION AND LITERATURE REVIEW  
Hypoxis hemerocallidea Fisch. C.A.Mey. & Avé-Lall (African Potato) is one of the most 
important medicinal plants in South Africa. The major component of the plant is hypoxoside 
(3.1), a 1,5-diaryl-1-penten-4-yne (Kruger et al., 1994). The related species Hypoxis 
colchicifolia Bak. is also used in traditional medicine. One of the medicinal uses of H. 
colchicifolia is for the treatment of diabetes. This work describes the composition and 
antidiabetic activity of the MeOH extract of H. colchicifolia. 
 While writing this thesis (December 2014), a paper was published in which Bassey et al. 
(2014) reported the isolation of two new phenolic glycosides, 3-hydroxy-4-O-β-D-
glucopyranosylbenzaldehyde and 1,5-bis(3,4-dihydroxyphenyl)-1,2-dihydroxy-4-pentyne-2-p-
coumaroyl-β-D-gluco-pyranoside from the corms of H. colchicifolia. They also identified the 
norlignan glycosides hypoxoside, dehydroxyhypoxoside and bis-dehydroxyhypoxoside. 
3.1.1 The Hypoxidaceae family 
Hypoxidaceae is a family of flowering plants, grouped in the order Asparagales of the 
Monocotyledons. The family consists of probably more than six genera with about 100-200 
species (List, 2013). The family members are small to medium herbs, with grass-like leaves 
and an invisible stem, modified into branches. Hypoxidaceae are herbaceous perennial herbs 
with corms or rhizomes, some have tubers. The flowers are born on leafless shoots, with three 
article fittings, radially symmetric with six yellow petals (Hutchings, 1996; Leistner, 2000). 
1.2 The genus Hypoxis  
The name Hypoxis is derived from Greek with ‘hypo’ meaning ‘below’ and ‘oxy’ referring to 
the base ends of the ovary or fruit. The Hypoxis genus was established by Linnaeus in 1759 
and then alternately assigned within and outside the family Amaryllidaceae 
(Monocotyledons). In 1964 it was moved to the monophylitic family Hypoxidaceae (Guide to 
the flora of the Carolina, 2005).  There are 96 known species of Hypoxis in Africa, 16 in 
North and South America, and 7 in Southeast Asia and Australia. 
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3.1.3 Phytochemistry of Hypoxidaceae  
Norlignans are the characteristic class of secondary metabolites isolated from Hypoxis. The 
chemical structures of norlignans are composed of phenylpropane (C6-C3) and phenylethane 
(C6-C2) units (Suzuki and Umezawa, 2007). Based on the linkage position between the two 
units, they are classified into three groups: norlignans from conifers with C7-C8′ linkage; 
norlignans from monocotyledons with a C8-C8′ linkage; norlignans from other plant sources 
with C8-C9′ linkage (Suzuki and Umezawa, 2007). Recently, Suzuki and Umezawa (2007) 
proposed biosynthetic pathways for the formation of three groups of norlignans from 





















Figure 3.1: Biosynthetic scheme for the norlignans. 
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In 1982 Marini-Bettolo et al. isolated an unsaturated norlignan glycoside from the rhizomes of 
H. obtusa collected in Mozambique. It was the first compound identified from the 
Hypoxidaceae and therefore named hypoxoside (3.1), ((E)-1,5-bis[(3'-hydroxy-4'-O-β-D-
glucopyranosyloxy)-phenyl]-1-penten-4-yne) (Marini-Bettolo et al., 1982). The isolation of 
this compound was also reported from H. hemerocallidea and H. nyasica (Drewes et al., 
1983; Galeffi and Multari, 1987). 
The other compounds isolated from the various Hypoxis species are obtuside A (3.2), obtuside 
B (3.3), zeatin (3.4), zeatin glucoside (3.5), obtusaside (3.6) from the H. obtusa (Msonthi et 
al., 1990); acuminoside (3.7) from H. acuminata; mononyasine A (3.8), mononyasine B (3.9),  
nyaside  (3.10) (Marini-Bettolo et al., 1991) and nyasicoside (3.11) (Messana et al., 1989)  
from H. nyasica; interjectin (3.12) from H. interjecta and H. multiceps (Marini-Bettolo et al., 
1991) and β-sitosterol (3.13) from the corms of H. hemerocallidea, popularly known as the 








3.4 Zeatin     
































Figure 3.2: Compounds isolated from Hypoxis. 
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3.1.4 Medicinal uses and biological activity of Hypoxis species 
According to Appleton (2004), eleven species of the genus Hypoxis are used for traditional 
purposes throughout southern Africa. However, a survey of the most popular medicinal plants 
marketed in South Africa showed that only two species, H. hemerocallidea and H. 
colchicifolia, are routinely sold, especially on the markets in KwaZulu-Natal (Cunningham, 
1988). The high quantities of these species marketed in Southern Africa put them under threat 
of extinction. 
The corm of H. hemerocallidea (H. rooperii)  known as African potato, is widely used in 
traditional African medicine for the treatment of many general ailments: infusions are used as 
antiemetics, to treat dizziness, bladder disturbances, insanity (Verschaeve and Van Staden, 
2008), wounds and burns (Eloff et al., 2008), allergies, ulcers, arthritis, hypercholesterolaemia 
and infertility (Mills et al., 2005). The juice is used to treat burns, prostate problems, testicular 
tumours, benign prostatic hyperplasia (BPH) and urinary tract infection (Drewes et al., 2008; 
Verschaeve and Van Staden, 2008). Plant decoctions have purging effects (Aremu et al., 
2010). 
The aqueous extracts of African Potato have anti-inflammatory, anti-diabetic and 
antinociceptive properties in rats and mice (Ojewole, 2006). Gaidamashvili  and van Staden 
(2002)  reported that the ethanolic extracts of fresh leaves of H. hemerocallidea is active 
against Staphylococcus aureus, Enterococcus faecalis, Escherichia coli and Pseudomonas 
aeruginosa with MIC ≤ 0.63 mg mL-1. 
The aqueous extract (corms) of H. colchicifolia (Figure 3.3) is used to treat diabetes (Erasto, 
2005), HIV, inflammatory conditions, impotence and sterility, hysterics and is used as a tonic 
and an emetic (Ncube et al., 2013). Nair also reported its use for heart problems, impotency, 
female infertility, insanity and as a vermin killer (Nair, 2006).   
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Figure 3.3: H. colchicifolia corms. 
 
H. colchicifolia (leaves) had good COX-2 (cyclooxygenase) inhibitory activity (Aremu et al., 
2010). The aqueous and ethanolic extracts of H. colchicifolia leaves were found to inhibit 
angiotensin converting enzyme (ACE) at a concentration of  333.3 ng mL-1 (Nair, 2006). 
3.1.5 Hypoxis colchicifolia 
H. colchicifolia (H. latifolia) (Figure 3.4) is after H. hemerocallidea the second most 
important Hypoxis medicinal species with commercial value in South Africa. Although it is 
widely used in traditional medicine, the main secondary metabolites were not identified until 
now.* One of the medicinal uses of H. colchicifolia is for the treatment of diabetes (Appleton 
et al., 2012). 
The plants grow in grassland areas with a height of 25-60 cm and have big underground 
tubers that allow it to survive the constant grass fires common to this vegetation type. The 
leaves are long and erect, are stiff and almost hairless. The leaves die during the winter 
months and the new flowers appear after the early spring rains from the apex of the rhizome.  
                                                                
*While writing this thesis (December 2014), a paper on the chemistry of H. colchicifolia was published (Basset 
et al., 2014). 
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Figure 3.4: H. colchicifolia. 
H. colchicifolia occurs widespread from the eastern coast to the interior of southern Africa 
and occurs in the Eastern Cape and KwaZulu-Natal provinces of South Africa (Van Wyk et 
al., 2005). It is found on sandy or poor soils in grassland. 
3.2 RESULTS AND DISCUSSION  
In a previous investigation in our research group it was shown that the crude methanol 
extracts of both H. hemerocallidea and H. colchicifolia lowered the blood glucose level of 
STZ-induced rats and, therefore, that these two plants have antidiabetic activity (Thring and 
Weitz, 2006).  
The phytochemistry of H. hemerocallidea (syn. H. rooperi) has been investigated previously 
(Drewes et al., 2008; Drewes et al., 1983; Drewes et al., 1989; Kruger et al., 1994; Laporta et 
al., 2007). When this project was initiated, nothing had been published on the phytochemistry 
of H. colchicifolia and therefore it was decided to investigate the phytochemistry and 
antidiabetic activity of H. colchicifolia. While writing this thesis (December 2014), a paper on 
the chemistry of H. colchicifolia was published (Bassey et al., 2014).  
3.2.1 Isolation of compounds by preparative HPLC 
HPLC was used for the analysis and fractionation of the MeOH extract of H. colchicifolia 
corms.  In the chromatogram obtained on a semi-preparative column (Figure 3.14), four peaks 
were observed. Three of the peaks (P2 - P4) had closely related retention times. By using the 
same HPLC method, the MeOH extract was separated into four fractions (F1 – F4) 
corresponding to the four peaks (P1 – P4) in the chromatogram.  
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NMR analysis of F1 (Figure 3.15) showed that it consisted of a small amount of complex 
tannins and carbohydrates and this fraction was not investigated further. Fraction F2 (Figure 
3.16) consisted of a single compound, hypoxoside (3.1), which was first isolated from H. 
nyasica (Marini-Bettolo et al., 1982) and then from H. hemerocallidea  (Drewes et al., 1983). 
Fraction F3 consisted of a mixture of two deoxy analogues of hypoxoside named 
dehydroxyhypoxoside A (3.14) and dehydroxyhypoxoside B (3.15) in 3:1 ratio. Fraction F4 
consisted of a single compound, bis-dehydroxyhypoxoside (3.16). 
A contaminant 3.17, widely used in industry as an intermediate for the production of epoxy 
resins (Saiyood et al., 2010), was isolated from the ethyl acetate-soluble material of the 
methanol extract.   
Although the isolation of 3.15 and 3.16 have been described in literature (Bassey et al., 2014; 
Kruger et al., 1994; Laporta et al., 2007), there are no NMR data for these compounds in the 
literature. The authors in these three papers based the structures of 3.15 and 3.16 on LC-MS 
data. Compound 3.14 has not yet been reported. Herewith, the NMR spectra of 3.1 and 3.14 – 
3.16 are assigned. 
3.2.2  Hypoxoside (3.1) 
Fraction F2 consists of a single compound, which was identified as hypoxoside (3.1).  In the 
HPLC chromatogram, the retention time of F2 was the same as that of the major peak in the 
methanol extract of H. hemerocallidea. The structural elucidation of 3.1 isolated by Marini-
Betollo et al. and Drewes et al. was based on NMR studies of the peracetylated compound 
(Drewes et al., 1983; Marini-Bettolo et al., 1982). In the literature, there is only a single report 
on the NMR assignment of the free phenolic 3.1 (Laporta et al., 2007). Upon careful 
inspection, we have observed several discrepancies in the NMR assignments by Laporta et al. 
and since the structures of derivatives of 3.1 are based on the NMR data of 3.1, it is important 
that the assignments of the NMR spectra of this compound should be unambiguous. 
Therefore, we have reinvestigated the NMR assignments of 3.1. 
The 1H and 13C NMR spectra of 3.1 are given in Plate 1a and Plate 1b, respectively. The 
assignment of the spectra was based on interpretation of the DEPT-135, 1H,1H-COSY, 
1H,13C-HSQC and 1H,13C-HMBC spectra. In the 1H NMR spectrum, the resonances for the 
five-carbon backbone of 3.1 were observed at δH 6.57 (br d, J = 15.7 Hz, H-1) and δH 6.13 (dt, 
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J = 15.7 and 5.7 Hz, H-2) for the trans-alkene and δH 3.28 (dd, J = 5.7 and 1.5 Hz) for H-3. 
The resonance of H-3 was partly obscured by the solvent peak. The corresponding 13C NMR 
resonances were observed at 131.8 (C-1), 124.5 (C-2), 23.3 (C-3), 86.4 (C-4) and 83.3 (C-5). 
C-1, 2 and 3 were assigned from the 1JCH correlations with H-1, 2 and 3 respectively, 
observed in the HSQC spectrum. The two acetylenic carbons C-4 and C-5 was assigned based 
on the 3JCH  correlations with H-2 and H-3, respectively, in the HMBC spectrum. 
In hypoxoside (3.1), the two aryl rings attached to C-1 and C-5 have the same substitution 
pattern and the assignment of resonances to a specific ring was not crucial for the structural 
elucidation of 3.1. However, to assist with the structural elucidation of analogues of 
hypoxoside (3.1) where the two rings have different substitution patterns, it is important that 
the assignment of the resonances to the two rings of 3.1 must be unambiguous.   
Both rings display the three aromatic protons as ABX spin systems. The resonances of H-5' 
and H-5'', which have only ortho coupling, overlap and are observed as a two-proton doublet 
(J = 8.3) at δH 7.12. To differentiate between H-2' / H-6' and H-2'' / H-6'', the correlations 
observed in the HMBC spectrum were crucial. The resonances at δH 6.92 (dd, J = 2.0 Hz) and 
δH 6.83 (dd, J = 8.3 and 2.0 Hz) both correlated to the resonance at δC 131.8 (C-1) and were 
assigned to H-2' and H-6', respectively. Likewise, the resonances at δH 6.90 (d, J = 2.0 Hz) 
and δH 6.87 (dd, J = 8.3 and 2.0 Hz) correlated both to the resonance at δC 83.3 (C-5) and 
were assigned to H-2'' and 6'', respectively.   
The two anomeric protons of the glucose moieties were observed at δH 4.79 and 4.75 (d, J = 
7.5 Hz). The linkages through oxygen of the sugars moieties and C-4' and C-4'' of the 
aromatics rings were derived from the HMBC spectrum (Plate 1e), where the anomeric 
protons (H-1''' and H-1'''', δH 4.79 and 4.75) correlated with C-4' and C-4'' (δC 146.9 and 
146.3). The assignments of the methine carbohydrate carbons were also based on the 
correlations observed in the HMBC spectrum. For each of the glucosyl carbons, separate sets 
of resonances were observed for the two carbohydrate moieties in the 13C NMR spectrum; 
however, the chemical shifts were so close to each other that the resonances could not be 
assigned to the individual sugar moieties. 
The long-range correlations observed for 3.1 are illustrated in Figure 3.5. The NMR data of 
3.1 are summarized in Table 3.1. 
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Figure 3.5: Key HMBC (1H→13C, arrow) and key 1H−1H COSY (bold) correlations for 3.1. 
 
 
Analysis of 3.1 by high-resolution mass spectrometry (Plate 1h) using electrospray ionization 
in the negative mode show a peak at m/z 605.1868 [M-H]-, which correlated with the 
molecular formula of C29H34O14. Additional peaks in the negative mode were observed at m/z 
641.2382, corresponding to a chloride adduct [M+Cl]-, C29H34O14Cl, and a peak at m/z 283.13 
(C17H12O4). The last peak indicated the loss of two glucosyl moieties to form the aglycone. 
The IR spectrum revealed absorption bands at 780 and 860 cm-1 suggesting C-H rocking 
vibrations. The C-H in-plane bending is shown by the stretching vibration band at 2894 cm-1. 
The absorption bands at 1246 and 3332 cm-1 denote OH bending and stretching, respectively. 
The bands at 896 and 1014 cm-1 suggest the C-H out-of-plane deformation when attached to a 
carbon by a double bond (C=C-H). The C=C in an aromatic ring is shown by two bands of 
medium intensity at 1510 and 1587 cm-1 (Nair, 2006). 
The UV spectrum was obtained from the diode-array detection of 3.1 in the HPLC. The UV 
spectrum of 3.1 shows three absorption bands respectively at λ 210 (maximum absorption), 
257 and 291 nm. The same absorption profile was found by Kruger and Laporta, confirming 
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Table 3.1: 1H and 13C NMR data of hypoxoside 3.1 in CD3OD (J in Hz). 
 
Position  Assignment by Laporta et al 2007 
 δH δC δH [(CD3)2CO] δC (CD3OH) 
1 6.57,  d (15.7) 131.8 6.51 131.6 
2 6.13, dt (15.7, 5.7) 124.5 6.08 (15.7, 5.5)                 124.3 
3 3.28, dd, (5.7, 1.5) 23.3 3.23 23.2 
4 - 83.3 - 86.2 
5 - 86.3 - 83.2 
1' - 134.6 - 114.4 
2' 6.92, d (2.0) 114.5 7.08 118.2 
3' - 148.5, 148.1 - 148.3, 148.0 
4' - 146.9 or 146.3 - 146.8; 146.2 
5' 7.12, d (8.3) 118.9 or 118.5 6.85 120.0 
6' 6.83, dd (7.0, 1.5) 119.4 6.82 124.5 
1'' - 120.3 - 134.3 
2'' 6.90, d (2.0) 120.1 7.06 118.5 
3'' - 148.5, 148.1 - 148.3, 148.0 
4'' - 146.9 or 146.3 - 146.8; 146.2 
5'' 7.12, d (8.3) 118.9 or 118.5 6.87 114.3 
6'' 6.87, dd (8.3, 2.0) 124.7 6.77 119.3 
1'''/1'''' 4.79 or 4.75, d 
(7.5) 
104.4 or 104.0 4.74; 4.72, d 
(7.2) 
104.1; 103.7 
2'''/2'''' 3.52-3.44, m 74.9 or 74.8 3.40–3.37, m 78.2 
3'''/3'''' 3.52-3.44, m 77.64 or 77.60 3.48–3.42, m 74.8 
4'''/4'''' 3.50-3.41, m 71.3 3.40–3.37, m 71.2 
5'''/5'''' 3.50-3.41, m 78.4, 78.3 3.48–3.42, m 77.6 
6'''/6'''' 3.90, 3.72, br d 
(12.2) 
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3.2.4 Bis-dehydroxyhypoxoside (3.16) 
The MS data of the three major compounds observed in the HPLC indicated that they are 
hypoxoside (3.1) (Rt 13.072), deoxy derivative(s) of hypoxoside (Rt 13.655) and a dideoxy 
derivative of hypoxoside (Rt 14.339). NMR data indicated that the dideoxy derivative 3.16 
has two identical aryl rings on C-1 and C-5. Since the NMR data of 3.16 was used to assign 
the structures of the deoxy-derivatives, the NMR assignment of 3.16 will be discussed first. 
Compound 3.16 was obtained as a brown amorphous solid. The high-resolution mass 
spectrum of 3.16 (Plate 3h) using electrospray ionization in the positive mode showed a peak 
at m/z 597.1950 [M+Na]+ corresponding to a molecular formula of C29H34O12 (that indicated 
13 indices of hydrogen deficiency). In the negative mode peaks were observed at m/z 
609.2321 [M+Cl]-, C29H34O14Cl, corresponding to a chloride adduct, and m/z 411.1911 
(C23H23O7) and 249.1205 (C17H13O2), indicating the loss of one and two glucosyl moieties, 
respectively, to form the aglycone (Bassey et al., 2014).  
Although the structure of 3.16 was proposed by Kruger et al. (1994), Laporta et al. (2007), 
and Bassey et al. (2014), these authors only reported MS data and the NMR of 3.16 was 
reported . Herewith we describe the first NMR assignment of 3.16. 
The NMR profile for the 5-carbon backbone (C-1 - C-5) of 3.16 is similar to that of 3.1. Of 
importance are the unambiguous assignments of C-1 and C-5 in the 13C NMR spectrum. In 
the spectrum of 3.16 the assigned to H-1 (δH 6.58, d, J =15.8 Hz) correlated with the 13C 
resonance at δC 131.7, which was assigned to C-1. To differentiate between the two acetylenic 
carbon resonances, the correlation in the HMBC spectrum of H-2 (6.17, dt, J = 15.8, 5.8 Hz) 
to the carbon resonance at δC 86.5 was used to assign this resonance to C-4. Therefore, the 
resonance at δC 83.5 was assigned to C-5. 
Further analysis of the 1H and 13C NMR spectra (Plate 3a and Plate 3b, respectively) revealed 
the presence of two para-substituted aryl rings. In the 1H NMR spectrum, the resonances of 
H-3',5' and H-3'',5'' had the same chemical shift at δH 7.04 and a 4-proton doublet (J = 9.1 Hz) 
was observed. However, there was a slight difference in chemical shift for the resonances of 
H-2',6' and H-2'',6'' at δH 7.04. The assignment of the resonances was based on correlations 
observed in the HMBC spectrum. The two-proton doublet at δH 7.37 (J = 9.0 Hz) correlated 
with the carbon at δC 82.0 (C-5) and could be assigned to C-2'',6''. Likewise the two-proton 
34 | P a g e  
 
doublet at δH 7.33 correlated with the resonance at δC 130.4 (C-1) and could be assigned to C-
2', 6'.  
The linkages between the aromatic ring and sugar moieties at C-4' and C-4'' were derived 
from the HMBC spectrum (Plate 3d) in which the anomeric protons H-1''',1'''' (δH 4.91) were 
correlated to the phenyl C-4' and C4'' at δC 158.7, 158.5. 
 
Figure 3.6: Key HMBC (1H→13C, arrow) and key 1H−1H COSY (bold) correlations for 3.16. 
 
As can be expected, the IR spectrum of 3.16 (Plate 3f) is same as that of 3.1 and revealed 
absorption bands at 780 and 860 cm-1 suggesting C-H rocking vibrations. The C-H in-plane 
bending is shown by the stretching vibration band at 2894 cm-1. The absorption bands at 1246 
and 3332 cm-1 denote OH bending and stretching respectively. The bands at 896 and 1014 cm-
1 suggest the C-H out-of-plane deformation when attached to a carbon by a double bond 
(C=C-H). The C=C in an aromatic ring is shown by two bands of medium intensity at 1510 
and 1587 cm-1. 
The UV spectrum of 3.16 (Plate 3g) showed two absorption bands respectively at 210 
(maximum absorption) and 259 nm. This spectrum differs from 3.1 and 3.14 because the band 
at 300 nm does not appear. This is contrary to the UV spectrum presented by Kruger (1994) 
and also by Laporta (2007) for this compound.   
3.2.3 Dehydroxyhypoxoside A (3.14)  and B (3.15) 
HPLC analysis of fraction 3, obtained by preparative HPLC separation of the crude extract, 
showed the presence of two compounds, a major and a minor compound. Initially it was 
assumed that the fraction was contaminated with 3.16 (Rt 14.339), but after careful 
consideration of the retention times it was concluded that the second (minor) peak with Rt = 
14.26 was indeed a different compound from 3.16. We were not able to separate these 
compounds.  The compounds were identified as two deoxy derivatives of hypoxoside which 
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we named dehydroxyhypoxoside A (3.14) and dehydroxyhypoxoside B (3.15) and they were 
isolated as a mixture in a 1:2 ratio of these compounds. 
The mixture of the compounds 3.14 and 3.15 was obtained as a brown, amorphous solid. The 
high-resolution MS using electrospray ionization in the negative mode showed a peak at m/z 
589.1915 [M-H]- corresponding to a molecular formula of C29H33O13 (that indicate 13 indices 
of hydrogen deficiency). Peaks at m/z 625.2342 corresponding to [M+Cl]- C29H34O13Cl (a 
chlorine adduct), m/z 427.1825 (C23H23O8) and 265.1147 (C17H12O3) were also observed. The 
later peaks indicated the loss of one and two glucosyl moieties, respectively, to form the 
aglycone.  
The presence of 3.14 (refer to as dehydroxyhypoxoside) in H. hemerocallidea has been 
reported by Kruger et al. and Laporta et al., whereas Bassey et al. described the isolation of 
3.14 from H. colchicifolia (Bassey et al., 2014; Kruger et al., 1994; Laporta et al., 2007). 
However, in all publications only MS data were provided and no NMR data were reported.  
The 1H and 13C NMR spectra showed that fraction 3 consisted of a 2:1 mixture of compounds. 
Both the major and the compounds had structural elements in common with 3.1 and 3.16. In 
the 1H NMR spectra, a slight but clearly discernible chemical shift difference was observed 
for H-1 of 3.1 (δH 6.57) and 3.16 (δH 6.64). In the spectrum of fraction 3, the major 
component (3.15) had a peak for H-1 at δH 6.58, indicating that the A-ring had most likely the 
same substitution pattern as hypoxoside (3.1), whereas H-1 for the minor component (3.14) 
resonated at δH 6.64,  which is in agreement with an A-ring with a substitution pattern similar 
to that of bisdehydroxyhypoxoside (3.16). Analysis of the aromatic region of the 1H NMR 
spectrum confirmed that the mixture consists of two isomeric compounds, the major isomer 
3.15 with an 1,3,4-trisubstituted A-ring and a 1,4-disubststituted B-ring and the minor isomer 
3.14 with a 1,4-disubstituted A-ring and a 1,3,4-trisubstitued B-ring. 
The key to determine on which ring the OH was, was the analysis of the HMBC (Plate 2h) 
spectrum in which it was possible to establish correlations between H-2' and C-1 for 
compound 3.14 and H-2'' and C-5 for compound 3.15. 









































Figure 3.7:  Key HMBC (1H→13C, arrow) correlations for isomers 3.14 and 3.15. 
The IR spectrum of the compounds 3.14 and 3.15 has the same profile as described for 3.1 
and 3.16. The UV spectrum of 3.14 and 3.15 shows three absorption bands at 210 (maximum 
absorption), 258 and 290 nm. The same UV profile was reported by Kruger (1994) and 
Laporta (2007). 
3.2.4 Bisphenol A diglycidyl ether (3.17) 
The structural determination of 3.17 was achieved through a combination of different 











The analysis of the COSY (Plate 4c) and 1H NMR spectra (Plate 4a) showed the presence of a 
para-substituted aromatic ring at δH 6.89 and δH 7.13. The COSY spectrum allowed us to 
observe the correlation between H-5 (δH 7.13, d, J = 9.0 Hz) and H-6 (δH 6.81, d J = 8.9 Hz). 
The HSQC spectrum (Plate 4d) showed that in the aromatic ring C-5 (δC 157.4) correlates to 
H-5 at δH 7.13, and C-6 (δC 114.3) was attached to H-6 at δH 6.83.  
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A gem-dimethyl group was observed at δH 1.64 (6H, s, H-9) (Plate 4a), and HMBC showed 
the correlation between H-9 and C-8 (δC 41.7) and C-7 (δC 143.4). In the NMR spectrum, the 
two diastereotopic protons on C-3 were observed as two doublet of doublets at δH 4.17 (dd, J 
= 11.0 and 3.2) and δH 3.96 (dd, J = 11.0 and 5.5). H-2 was observed as a narrow multiplet at 
δH 3.34 and the two terminal epoxy protons were observed as a triplet at δH 2.89 (J = 4.5 Hz) 
and a doublet of doublet at δH 2.74 (J = 5.0, 2.6 Hz). The NMR data of this compound was in 
agreement with the data recorded in the literature (Terasaki et al., 2006). In LR-MS a peak 
was observed at m/z 359.3477 [M+H2O]+ . 
 
Figure 3.8: Key HMBC (1H→13C, arrow) and key 1H−1H COSY (bold) correlations for 3.17. 
 
Bisphenol A diglycidyl ether is an industrial chemical used as intermediate for the production 
of epoxyphenolic resins, polycarbonates, polyacrylates, plastics, and coatings for food / drink 
packaging (Saiyood et al., 2010). The area where the plant material was collected is often 
frequented by people and is also polluted with the food containers. The presence of 3.17 in the 
corms of H. colchicifolia corms is most likely as a result of pollution of the environment. It 
has been reported that 3.17 can be absorbed by plants (Saiyood et al., 2010).  
 
3.3 ANTIDIABETIC ACTIVITY AND CYTOTOXICITY OF THE METHANOL 
EXTRACT OF H. COLCHICIFOLIA 
3.3.1 Cytotoxicity screening 
In type 2 diabetes, the body produces insulin, but the cell does not utilize it properly resulting 
in a high glucose concentration in the body. In the cell-based assay the effect of an extract or 
compound on the utilization of glucose is investigated to probe the antidiabetic activity of the 
extract or compounds. However, it was important to determine, whether the extract of H. 
colchicifolia was cytotoxic to the cell lines used. 
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The first assay determined the viability of liver and muscle cell lines in the presence of the 
crude extract of H. colchicifolia. The viability of a liver cell line (Chang) was determined by 
treating the cells with the extract at 12.5, 25 and 50 μg mL-1 and the viability was determined 
at 12, 24 and 48 h (Figure 3.9).  
 
Figure 3.9: Cell viability of liver cell line (Chang) treated with H. colchicifolia extract at three 
concentrations (12.5, 25 and 50 μg mL-1) after 12, 24 and 48 h. ٭ = p < 0.05 in comparison to 
control. 
The experiment was repeated with a muscle cell line (C2C12) and the results are shown in 
Figure 3.10. 
  
Figure 3.10:  Cell viability of muscle cell line (C2C12) treated with H. colchicifolia extract 
at three concentrations (12.5, 25 and 50 μg mL-1) after 12, 24 and 48 h. ٭ = p < 0.05 in 
comparison to control. 
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The results of cell viability of both the liver cell line (Chang) and the muscle cell line 
(C2C12) when treated with different concentrations (12.5 - 50 μg mL-1) of the MeOH extract 
of H. colchicifolia corms show that the cell viability remains constant after 48 h. It can be 
concluded that the MeOH extract (corms) of H. colchicifolia are not toxic to these cells. 
3.3.2 Glucose utilization when the cells are treated with the methanol extract of H. 
colchicifolia 
 
Figure 3.11: Effect of H. colchicifolia concentration (12.5, 25 and 50 μg mL-1) on glucose 
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Figure 3.12: Effect of H. colchicifolia concentrations (12.5, 25 and 50 μg mL-1) on glucose 
utilization in a liver cell line (Chang) after 12, 24 and 48 h. ٭ = p < 0.05 in comparison to 
control. 
  
The results showed that when the Chang liver cell line and the C2C12 muscle cell line were 
treated with the MeOH extract of H. colchicifolia, the level of glucose significantly decreased 
after 12 h at extract concentrations of 25 and 50 μg mL-1, whereas for an extract concentration 
of 12.5 μg mL-1, the level of glucose significantly decreased only after 24 h.  
The results further showed that the MeOH extract of H. colchicifolia had glucose lowering 
effects and low toxicity in vitro. An unpublished study in rats where diabetes was induced by 
STZ, reported that the methanol extract of corms of H. colchicifolia and H. hemerocallidea 
reduced the level of blood glucose in 5 h at 45 mg kg-1 (Thring and Weitz, 2006). Ojewole 
(2006) also observed that the aqueous extract of the related species H. hemerocallidea (800 
mg kg-1) reduced blood glucose in experimental animals after 8 h of treatment. 
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3.3.3 Glucose utilization when the cells were treated with the compounds    
 
Fig 3.13: The effects of H. colchicifolia compounds on glucose utilization in muscle (C2C12) 
cell line. ٭= p < 0.05 in comparison to the control. 
 
When the muscle cell line was treated with the individual fractions from the MeOH extract of 
H. colchicifolia [P1 (mixture of sugars and tannins), P2 (3.1) P3 (3.14 and 3.15) and P4 
(3.16)], the most active fractions were P1 and P3.  
This study was the first to prove antidiabetic activity of the MeOH extract of H. colchicifolia. 
It can be concluded that H. colchicifolia has potential for future antidiabetic drug 
development. 
 
3.4 EXPERIMENTAL  
3.4.1 General experimental procedures 
The solvents used in this project, i.e. ethyl acetate, DCM, hexanes (mixture of hexane 
isomers), and MeOH were of analytical grade. HPLC grade MeOH was used for the HPLC 
procedures. The water was purified in a PureLab Ultra ELGA® system. 
For the separation and purification of compounds, centrifugal chromatography (Chromatotron 
model 7924, Harrison Research) or column chromatography were used. The circular 
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Chromatotron plates were coated with preparative silica gel (2 or 4 mm thickness, Merck 
7749 with gypsum binding agent). Column chromatography was performed with silica gel 60 
F254, (40-63 μm, Merck). Thin-layer chromatography (TLC) plates (Kieselgel 60 F254, 0.25 
mm) stained with anisaldehyde/sulfuric acid were used for the qualitative analysis of fractions 
and compounds. The stain solution was made as follows: In a 1 L volumetric flask,   845 mL 
of MeOH was cooled in an ice bath, while shaking to ensure homogeneity, 100 mL of acetic 
acid was added followed by addition of 40 mL of concentrated sulfuric acid and 5 mL of 
anisaldehyde. The solution was stored in a fridge. 
HPLC was used for the isolation and qualitative analysis of the compounds. The isolation was 
performed by semi-preparative HPLC using a LC-20AB P2000 pump equipped with a SIL-
20A autosampler and a SPD-20A UV detector (all supplied by Shimadzu). The isolation was 
achieved on a Luna 5μm C18 (250 x 10 mm) semi-preparative column (Phenomenex). A 
mobile phase consisting of 1% acetic acid in water (solvent A) and MeOH (solvent B) in a 
gradient program [45% MeOH (3 min), 45 – 50% MeOH (5 min), 50 - 55% MeOH (9.5 min), 
55% (0.5 min)] at a flow rate of 3 mL min-1. Samples (15 mg mL-1) were injected (120 μL per 
injection) onto the column, which was maintained at a temperature of 40 ºC, and the eluant 
was monitored at wavelength range of 210 - 450 nm with a diode array UV detector. 
Qualitative analyses of fractions were carried out on a Kinetex 2.6 μm C18 (2) (100 x 4.6 
mm) column (Phenomenex). The separation was achieved using the same mobile phase 
described for the isolation of the compounds but a linear gradient of 15% in 5 minutes (40 to 
90%) at a flow rate of 0.4 μL min-1, using a detection wavelength of (210 - 450 nm). 
NMR spectra (1H, 13C, COSY, HSQC, HMBC and DEPT) Bruker Avance III 500 or Bruker 
Avance III 400 spectrometers were used. All spectra were recorded in deuterated solvents 
(CDCl3 and CD3OD) at 30 °C using either a 5 mm BBOZ probe or a 5 mm TBIZ probe. 
Chemical shifts (δ) are given in parts per million (ppm) and are referenced to a residual 
protonated solvent peak (CDCl3: 1H 7.26, 13C, 77.0, methanol-d4: 1H 3.31, 13C, 49.1). Peak 
multiplicities are designated as s for singlet, d for doublet, dd for doublet of doublet t for 
triplet, dt for doublet of triplet, m for multiplet. Coupling constants (J) are given in Hz.  
High-resolution mass spectral data were acquired on a time-of-flight Waters LCT Premier 
mass spectrometer using electrospray ionization in the positive or negative mode. Infrared 
spectra were recorded on a Perkin Elmer FT-IR (Fourier transform infrared spectroscopy) 
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spectrometer with universal ATR sampling accessory, optical rotations were determined using 
an ADP 440+ model polarimeter manufactured by Bellingham and Stanley. 
3.4.2 Collection of plant material 
The fresh corms of H. colchicifolia were collected in Hayfields, Pietermaritzburg in 
KwaZulu-Natal. The plant was identified by Prof. Drewes and a voucher (van Heerden 8) was 
deposited in the Bews Herbarium of the School of the Life Science, Pietermaritzburg campus, 
University of KwaZulu-Natal. The corms were washed with water and then cut into small 
pieces.  It was dried in an oven at 30 ºC for 3 days until reaching a constant weight. It was 
then ground with a mechanical mill to afford a mass of 423 g. 
3.4.3 Extraction and isolation of hypoxoside derivatives 
The powdered corms (423 g) were extracted successively with DCM:MeOH (1:1) and MeOH, 
for 24 h at room temperature. After each extraction, the solvent was filtered using Whatman® 
No 1 filter paper and concentrated under vacuum using a rotary evaporator. The extracts were 
then dried under high vacuum. The yields were 13.6 g for the MeOH:DCM (1:1) extract and 
25.2 g for the MeOH extract. On TLC and HPLC the contents of these two extracts were very 
similar and further investigations were performed on the methanol extract only. 
A portion of the dried MeOH extract (1 g) was fractionated by semipreparative HPLC. The 
extract was weighed out accurately and dissolved in HPLC-grade MeOH to obtain a 
concentration of 15 mg mL-1. The fresh solution (120 μL) was injected onto a semi-
preparative HPLC column with chromatography conditions described previously. Four 
fractions, F1 (Rt 4.291), F2 (Rt 17.024), F3 (Rt 17.677) and F4 (Rt 18.335), were collected 
manually according to the chromatographic profile shown in Figure 3.14. After repeated 
injections, fractions with the same retention times were combined and concentrated with a 
rotary evaporator under vacuum until complete removal of water. The yields were 55.6 mg, 
34.4 mg, 19.7 mg and 23.1 mg for fractions F1 to F4, respectively. 
The samples were dried under high vacuum to yield the compounds as brown powders. 
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Figure 3.14: HPLC profile of the methanol extract of H. colchicifolia on the preparative 
column. 
 
Solutions with a concentration of 1 mg mL-1 in MeOH were prepared of each fraction 
separately were injected in an analytical column with the aim to test the purity. Under the 
same chromatographic conditions described anteriorly were observed purity of each fraction 
as described in the Figures 3.15 to 3.18. 
 
Figure 3.15: HPLC profile of the fraction F1 on analytical column. 
 
45 | P a g e  
 
 
Figure 3.16: HPLC profile of the fraction F2 in analytical column 
 
 
Figure 3.17: HPLC profile of fraction F3 in analytical column. 
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Figure 3.18: HPLC profile of fraction F4 in analytical column. 
 
After analysing the NMR data, it was concluded that the fraction F1 corresponded to a 
complex mixture of tannins and sugars. This fraction was not investigated further. F2 
corresponded to hypoxoside (3.1), F3 contained a mixture of dehydroxyhypoxoside A (3.14) 
and dehydroxyhypoxoside B (3.15) and F4 consisted of bis-dehydroxyhypoxoside (3.16). 
Hypoxoside (3.1) was isolated as a brown solid. 1H NMR (500 MHz, CD3OD) δH 7.12 (2H, 
d, J = 8.3 Hz, H-5',5''), 6.92 (1H, d, J = 2.0 Hz, H-2'), 6.90 (1H, d, J = 2.0 Hz, H-2''), 6.87 
(1H, dd, J = 8.3, 2.0 Hz, H-6''), 6.83 (1H, dd, J = 8.3, 2.0 Hz, H-6'), 6.57 (1H, d, J = 15.7 Hz, 
H-1), 6.13 (1H, dt, J = 15.7, 5.7 Hz, H-2), 4.79 (1H, d, J = 7.5 Hz, H-1''' or H-1''''), 4.75 (1H, 
d, J = 7.5 Hz, H-1''' or H-1''''), 3.90 (2H, d, J = 12.2, Ha-6''',6''''), 3.72 (2H, br d, J = 12.2,  Hb-
6''',6''''), 3.52-3.44 (4H, m, H-2''',2'''',3''',3''''), 3.50-3.41(1H, m, H-4''',4'''',5''',5''''), 3.28 (2H, dd, 
J = 7.0 and 1.5 Hz, H-3) (Plate 1a); 13C NMR (100 MHz, CD3OD) δC 148.5, 148.1 (C-3',3''), 
146.9, 146.3 (C-4',4''), 134.6 (C-1'), 131.8 (C-1), 124.7 (C-6''), 124.5 (C-2), 120.3 (C-1''), 
120.1 (C-2''), 119.4 (C-6'), 118.9, 118.5 (C-5',5''), 114.5 (C-2'), 104.4, 104.0 (C-1''',1''''), 86.3 
(C-4), 83.3 (C-5), 78.4, 78.3 (C-5''',5''''), 77.64, 77.60 (C-3''',3''''), 74.9, 74.8 (C-2''',2''''); 71.3 
(2C, C-4''',4'''') 62.4 (2C, C-6''',6''''), 23.3 (C-3) (Plate 1b); [α]D20 = -70.1o; HRMS m/z 
605.1868  [M + H]+  C29H33O14 (cald 605.1870 for 100% ). UV (MeOH) λmax (nm) 210, 257, 
297. IR νmax (cm-1) OH (3332); CH (2893).   
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Dehydroxyhypoxoside A (3.14) was isolated as a brown solid substance. 1H NMR (500 
MHz, CD3OD): δH 7.33 (2H, d, J = 8.8 Hz, H-2',6'), 7.13 (1H, d, J = 8.2 Hz, H-5''), 7.04 (2H, 
d, J = 8.8 Hz, H-3',5'), 6.90 (1H, d, J = 2.1 and 2.0 Hz, H-2''), 6.87 (1H, d, H-6''); 6.58 (1H, d, 
J = 17.1 Hz, H-1), 6.15 (1H, m, H-2), 4.91 (1H, d, J = 8.0 Hz, H-1'''), 4.90 (1H, d, J = 7.8 Hz, 
H-1'''), 4.78 (1H, d, J = 7.5 Hz, H-1''' or H-1''''), 4.75 (1H, d, J = 7.5 Hz, H-1''' or H-1''''), 3.89 
(2H, br d, J = 12.0 Hz, Ha-6'''), 3.75-3.67 (1H, m, Hb-6'''), 3.52-3.36 (4H, m, H-2''',2'''',3''', 3''''), 
3.50-3.41 (4H, m, 4''',4'''',5''',5''''), 3.32 (2H, d, J = 6.0 Hz, H-3), (Plate 2a); 13C NMR (100 
MHz, CD3OD): δC 158.5 (C-4'), 148.5 (C-4''), 147.06 or 146.7 (C-3''), 133.1 (C-1'), 131.8 (C-
1), 128.9 (C-3'), 124.7 (C-6''), 124.1 (C-2), 120.3 (C-1''), 120.1 (C-2''), 118.9 or 118.5 (C-5''), 
117.9, 117.7 (2C, C-3',5'), 104.4 or 104.0 (C-1''',1''''), 101.0, 100.7 (2C, C-1''', 1''''), 86.3 (C-4), 
83.1 (C-5), 78.4, 78.3 (2C, C-5''',5'''') or 78.21, 78.18 (2C, C-5''',5''''), 78.02, 78.01 (2C, C-
3''',3''''), or 77.64, 77.60 (2C, C-3''',3''''), 74.9, 74.8 (2C, C-2''',2'''') or 74.93, 71.91 (2C, C-
2''',2''''), 71.3 or 69.9   (2C, C-4''',4''''), 62.55, 62.51, 62.4,  (2C, C-6''',6''''), 23.3 (C-3) (Plate 
2c); [α]20 = -67.3 HRMS m/z 589.1915 [M - H]+ C29H33O13 (cald 589.1921 for 100%);  UV 
(MeOH) λmax (nm) 210, 257, 297; IR νmax (cm-1) OH (3332), CH (2893.2).   
Dehydroxyhypoxoside B (3.15) was isolated as a brown solid substance. 1H NMR (500 
MHz, CD3OD): δH 7.35 (1H, t, J = 8.8 Hz, H-2'',6''), 7.13 (1H, d, J = 8.2 Hz, H-5'), 7.04 (2H, 
d, J = 8.9 Hz, H-3'',5''), 6.92 (1H, d J = 2.0, H-2'), 6.83 (1H, dd, J = 8.4 Hz and 1.9 Hz, H-6'), 
6.58 (1H, d, J =17.1 Hz, H-1), 6.15 (1H, m, H-2), 4.78 (1H, d, J = 7.5 Hz, H-1'''), 4.91 (1H, d, 
J = 8.0 Hz, H-1'''), 4.90 (1H, d, J = 7.8 Hz, H-1'''), 4.78 (1H, d, J = 7.5 Hz, H-1''' or H-1''''), 
4.75 (1H, d, J = 7.5 Hz, H-1''' or H-1''''), 3.89 (2H, br d, J = 12.0 Hz, Ha-6'''), 3.75-3.67 (1H, 
m, Hb-6'''), 3.52-3.36 (4H, m, H-2''',2'''',3''', 3''''), 3.50-3.41 (1H, m, 4''',4'''',5''',5''''), 3.32 (2H, d, 
J = 6.0 Hz, H-3), (Plate 2a). 13C NMR (100 MHz, CD3OD): δC 158.7 (C-4''), 148.5 (C-4''), 
147.06-146,7 (C-3'), 133.8 (2C, C-2'',6''), 134.5 (C-1''), 131.7 (C-1), 124.1 (C-2), 120.1 (C-2'), 
119.4 (C-6'), 114.5 (C-2'), 104.4 or 104.0 (C-1''',1''''), 101.0, 100.7 (2C, C-1''', 1''''), 86.3 (C-4), 
83.1 (C-5), 78.4, 78.3 (2C, C-5''',5'''') or 78.21, 78.18 (2C, C-5''',5''''), 78.02, 78.01 (2C, C-
3''',3''''), or 77.64, 77.60 (2C, C-3''',3''''), 74.9, 74.8 (2C, C-2''',2'''') or 74.93, 71.91 (2C, C-
2''',2''''), 71.3 or 69.9   (2C, C-4''',4''''), 62.55, 62.51, 62.4,  (2C, C-6''',6''''), 23.3 (C-3) (Plate 
2b); [α]20 = -67.3 HRMS m/z 589.1915 [M - H]+ C29H33O13 (cald. 589.1921);  UV (MeOH) 
λmax (nm) 210, 257, 297; IR νmax (cm-1) OH (3332), CH (2893.2).   
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Bis-dehydroxyhypoxoside (3.16) was isolated as a brown, amorphous solid. 1H NMR (500 
MHz, CD3OD): δH 7.35 (2H, d, J = 9.0, H-2'',6''), 7.33 (2H, d, J = 9.0, H-2',6'), 7.04 (4H, d, J 
= 9 Hz, H-3',3'', 5',5''), 6.64 (1H, br d, J = 15.8 Hz, H-1), 6.17 (1H, dt, J = 15.8, 5.8 Hz, H-2), 
4.91 (1H, d, J = 8.0 Hz, H-1''',1''''), 4.90 (1H, d, J = 7.8 Hz, H-1''',1''''), 3.89 (2H, dd, J = 12.0, 
2.2 Hz, Ha-6''',6''''), 3.71 (1H, dd, J = 12.2, 1.3 Hz, Hb-6''' or 6''''), 3.70 (1H, dd, J = 12.2, 1.3 
Hz, Hb-6''' or 6''''), 3.52-3.44 (4H, m, H-2''',2'''',3''',3''''), 3.43-3.88 (1H, m, H-4''',4'''',5''',5''''), 
3.28 (2H, dd, J = 7.0 and 1.5 Hz, H-3) (Plate 3a). 13C NMR (100 MHz, CD3OD): δC 158.7 (C-
4'') 158.5  (C-4'), 133.8 (2C, C-2'',6''), 133.1 (C-1'), 131.7 (C-1), 128.9 (2C, C-2',6'), 124.1 (C-
2), 119.7 (C-1''), 117.9, 117.7 (4C, C-3',3'',5',5''), 101.0, 100.7 (2C, C-1''', 1''''), 86.5 (C-4), 
83.2 (C-5), 78.21, 78.18 (2C, C-5''',5''''), 78.02, 78.01 (2C, C-3''',3''''), 74.93, 71.41 (2C, C-
2''',2'''')  71.41, 71.37 (2C, C-4''',4''''); 69.9 (C-5'''); 62.55, 62.51 (C-6''',6''''), 23.4 (C-3)  (Plate 
3c); [α]D20 = -64.4o; HRMS m/z 597.1950 [M + Na]+ C29H34O12Na (cald 597.1948);  UV 
(MeOH) λmax (nm) 210, 259; IR νmax (cm-1) OH (3332), CH (2893).   
3.4.4   Extraction and isolation of bisphenol A diglycidyl ether (3.17) 
Oven–dried (30 °C) and ground corms of H. colchicifolia (246 g) were extracted successively 
with DCM and MeOH at room temperature for 24 h to afford 5.1 g of the MeOH extract and 
326 mg of the DCM extract. 
The methanol extract (2.5 g) was fractionated on a short silica gel column by elution with 
increasing polarity of hexanes:EtOAc to yield 4 fractions after combination according to TLC 
profile, the 4th being a MeOH wash. Fraction 3 (corresponding to pure EtOAc) (236 mg) was 
purified twice on a Chromatotron with EtOAc:hexanes (3:7) resulting in the isolation of 









3.17 Bisphonol A diglycidyl ether  
Bisphenol A diglycidyl ether (3.17) was isolated as yellow, amorphous solid. 1H NMR (400 
MHz, CDCl3): δH 7.13 (4H, d, J = 9.0 Hz, H-6), 6.81 (4H, d, J= 9.0 Hz, H-5), 4.17 (2H, dd, 
J= 11.0, 3.2 Hz, H-3a), 3.96 (2H, dd J = 11.0, 5.5 Hz, H-3b), 3.34 (m, 2H, H-2), 2.89 (2H, t, J 
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= 4.5 Hz, H-1a), 2.74 (2H, dd, J = 5.0, 2.6 Hz, H-1b), 1.64 (6H, s, H-9) (Plate 4a). 13C NMR 
(100 MHz, CDCl3): δC 157.4 (C-4), 143.3 (C-7), 127.8 (C-6), 114.3 (C-5), 68.5 (C-3), 50.0 
(C-2), 44.6 (C-1), 41.7 (C-8), 32.0 (C-9) (Plate 4c); LR-MS m/z 359.3477 [M + H2O]+, 
C21H24O4 + H2O, (calcd. 359.1814). 
3.4.5 EVALUATION OF THE EFFECTS OF PLANT EXTRACTS AND 
COMPOUNDS ON GLUCOSE METABOLISM IN LIVER AND SKELETAL 
MUSCLE CELLS  
Cell culture experiments were performed by Ntethelelo Sibiya in the Physiology Research 
group of the School of Laboratory Medicine and Medical Science, University of KwaZulu-
Natal. 
 
3.4.5.1 Experimental cells  
 The cell lines used for the study were muscle (C2C12) and liver (Chang) cells which were 
donated by the Medical Research Council, Cape Town, South Africa. These cells were 
cultured in 25 mL flasks in DMEM and EMEM, respectively. Cells were used within 10 
passage numbers to limit batch-to-batch variation. Culture media were supplemented with 
10% foetal calf serum (FCS), 1% L-glutamate and 1% penicillin/ streptomycin/ fungizone. 
3.4.5.2 Cell culture protocol 
Cell culture was conducted using a well-established cell culture protocol. Briefly, muscle and 
liver cells were cultured in 10 mL DMEM or EMEM, respectively, at 37 ºC, 5% CO2 and 
89% relative humidity. The cells were allowed to grow and become confluent; thereafter the 
confluent cells were trypsinized with trypsin (1 mL) after washing three times with PBS. The 
trypsinized cells were sub-cultured into new flasks and some were stored in 10% DMSO at -
80 ºC for subsequent studies.   
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3.4.5.3 Cell seeding 
Both muscle (C2C12) and liver (Chang) cells were seeded at a density of 1.5×105 cells/mL in 
a 24-well cell culture plate. Both cell lines were allowed to grow and reach 80% confluence 
monolayer. 
3.4.5.4 Experimental design 
The effect of plant extract and compounds, were evaluated on glucose utilization and 
glycogen content in muscle and liver cells. 
3.4.5.5 Experimental protocol 
Each cell line was divided as follows: group 1 was treated with media containing glucose 
only, which served as the control, group 2 was treated with standard drug (insulin at 0.04 mg 
mL-1), and group 3 was treated with plant extract at various doses (12.5, 25 and 50 µg mL-1). 
This experimental protocol was used for all plant extracts and isolated compounds. To search 
for the influence of plant extracts on insulin action, all plant extracts or isolated compounds 
were combined with insulin. 
3.4.2.5.6 Glucose utilization model 
The glucose utilization experiment was performed as previously described by van de Venter 
et al. (2008) with slight modifications.  DMEM and EMEM contained glucose at a 
concentration of 28 mM. After seeded cells reached 80% confluence, the old media was 
replaced with fresh media. Plant extracts (100 µL) and plant extracts plus insulin (100 µL) 
was added into the media (1 mL) for treatment in each well. The culture plate was then 
incubated at the aforementioned conditions.  Glucose concentrations were measured at 0, 12, 
24 and 48 h intervals using a glucometer.  
3.4.5.7 Cell viability assay 
Cell proliferation was measured using the CellTiter-Glo Luminescent Cell Viability Assay 
(Technical Bulletin, Promega, Madison).  Cells were seeded in 96-well plates at a density of 
10 000 cells/well and incubated for 12, 24 and 48 h with the plant extracts (12.5, 25 and 50 µg 
mL-1). After every 12, 24 and 48 h, plates were equilibrated at room temperature for 30 
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minutes, assay reagent (100 μL) was added to each well, thereafter the plate was placed  on an 
orbital shaker for 2 minutes to induce cell lysis. After shaking, plates were incubated at room 
temperature for 10 minutes to stabilize the luminescence resonance, thereafter the 
luminescence was read on a Promega Microplate Luminometer. All plates had control wells 
containing media without cells for background correction. Data were expressed as percentage 
of viable cells (i.e. treatment value-blank/control value-blank), mean ± SEM for three 
replicates. 
3.4.5.8 Statistical analysis 
All data is expressed as means ± standard error of means (SEM). Statistical analysis was done 
using GraphPad Prism Instat Software (version 5.00, GraphPad Software, San Diego, 
California, USA). One-way analysis of variance (ANOVA) followed by Tukey-Kramer was 
used for analysis of differences between control and experimental groups. Values of p < 0.05 
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CHAPTER 4: A PHYTOCHEMICAL AND ANTIDIABETIC 
INVESTIGATION OF TERMINALIA SERICEA 
 
4.1 INTRODUCTION AND LITERATURE REVIEW  
4.1.1 The family Combretaceae 
The Combretaceae (Figure 4.1) is a family of flowering plants belonging to the order 
Myrtales, with about 600 species of trees, shrubs and lianas in 18 genera (Eloff et al., 2008). 
Combretaceae are common in subtropical and tropical regions (Fyhrquist et al., 2006).  
 
 
Figure 4.1: An example of a flower of Combretaceae. 
http://en.wikipedia.org/wiki/Combretaceae 
 
In traditional medicine in Africa several  species of the Combretaceae are used to treat many 
diseases, such as pneumonia, fever, headaches, abdominal disorders, venereal diseases 
including syphilis, earache, gallstones, diarrhoea, dysentery, gastric ulcers, bilharziasis, 
hookworm, nosebleeds, sore throats, colds, chest coughs, conjunctivitis, dysmenorrhoea, 
infertility in women, fattening babies, leprosy, scorpion and snake bites, among others (Eloff 
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4.1.2 The genus Terminalia 
Terminalia L. (Combretaceae) is a genus of large trees and includes 100 species disseminated 
in the tropical areas of the world. It is estimated that 40 species of Terminalia are endemic to 
Africa, 11 of which occur in the southern African region (Eloff et al., 2008). The name of this 
genus is derived from the Latin ‘terminus’, referring to the fact that the leaves appear at the 
very tips of the shoots. Trees of this genus are well known especially as a potential source of 
secondary metabolites, e.g. flavonoids, triterpenes and their derivatives, tannins, among 
others. Some of these compounds have antifungal, antibacterial, anti-cancer and 
hepatoprotective effects.  
4.1.3 Uses 
Terminalia species are used for diverse therapeutic applications such as diabetes, female 
infertility, abdominal pain, diarrhoea, and vermifuge, and known as a rich source of secondary 
metabolites, such as pentacyclic triterpenes and their glycoside derivatives, flavanones and 
chalcones (Ponou et al., 2011). 
Andrade-Cetto and Heinrich reported that two plants of the Combretaceae, Terminalia 
catappa L. (fruit) and Combretum farinosum Kunth (raw sap) are used in Mexico to treat 
diabetes (Andrade-Cetto and Heinrich, 2005). Kumar et al. found antidiabetic activity for the 
ethanol extract of T. chebula Retz. (fruits) in vivo (Kumar et al., 2006). 
Phenolic compounds such as gallic acid (4.1), ethyl gallate (4.2) and luteolin (4.3) with 
antineoplastic activities against human cancer cell lines have been isolated from the stem bark 
and leaves of T. arjuna (Roxb. Ex DC.) Wight & Am. (Fyhrquist et al., 2006), was also found 
that gallic acid is responsible for the antifungal activity of T. nigrovenulosa Pierre (bark) 
(Nguyen et al., 2013).  T. chebula (fruit) have been found to contain the tannin chebulinic acid 
(4.4), which decreases cell viability and inhibits cell proliferation in MCF 7  breast cancer, PC 
3 prostate cancer and HOS osteosarcoma cell lines in a dose-dependent manner (Fyhrquist et 
al., 2006). 






4.1 Galic acid                     
HO
OH










4.3 Luteolin  
 
The combretastatins are a group of stilbenes isolated from the stem bark of the South African 
bush willow tree, Combretum caffrum (Eckl.& Zegh.) Kuntze. A synthetic compound, 
combretastatin A-4-P (4.5), is a potential anticancer agent that is currently in clinical trial for 










4.5 Combretastatin A-4 phosphate  
The ethanol extract (stems) of T. phanerophlebia Engl. & Diels have anti-inflammatory 
activity (Nair et al., 2012). From the bark of T. ivorensis A. Chev., three saponins, including 
two dimeric triterpenoid glucosides possessing an unusual skeleton, ivorenoside A (4.6) and 
ivorenoside B (4.7), and ivorenoside C (4.8), were isolated. Compounds 4.7 and 4.8 exhibited 
scavenging activity against DPPH and ABTS+ radicals with IC50 values comparable to that of 
Trolox® (4.9) and 4.6 showed antiproliferative activity against MDA-MB-231 breast cancer 
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and HCT11 human cancer cell lines with IC50 values of 3.96 and 3.43 μM, respectively 







4.9 Trolox®  
The extracts of the leaves, stem and roots of T. mollis have antibacterial activity against 
Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, 
Salmonella typhi and Bacillus anthracis and antifungal activity against Candida albicans 
(Moshi et al., 2006). 
 
4.1.4 Review of Terminalia sericea 
 
Terminalia sericea Burch. ex. DC (Figure 4.2) is a medium-sized deciduous tree widely 
distributed in the tropical and warm temperate regions, especially in Africa (Moshi and 
Mbwambo, 2005). The plant has wide-spread traditional uses in eastern and southern African 
countries (Moshi and Mbwambo, 2005). 
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Figure 4.2: A young tree of Terminalia sericea. 
www.nparks.gov.sg/nursery/uploadfiles/terminaliasericea 
 
T. sericea has reddish-brown branches and the leaves are crowded at the ends of branches. 
The leaves are narrowly obovate-elliptic with smooth margins, blue-green above, paler below 
and densely covered with silvery hairs. It flowers mostly in September - January. The flowers 
are in axillary spikes and are pale yellow to creamy white. The fruit is an oval nut surrounded 
by a flat wing. The fruits are often parasitized and grow deformed (Masupa, 2012). T. sericea 
occurs in a variety of types of open woodlands particularly on sandy soils. It grows from 
Tanzania and the Democratic Republic of the Congo southwards to Angola and Namibia, 
Zimbabwe, Botswana, South Africa and Mozambique (Masupa, 2012). 
T. sericea is an important plant in traditional medicine and is in the top 50 most important 
African medicinal plants (Eloff et al., 2008; Masoko et al., 2005). The aqueous extracts of the 
leaves and roots and infusions are used in traditional medicine to treat coughs, diarrhoea and 
stomach aches and the leaves can be used as an antibiotic for wounds. The wood has 
commercial value and is used for constructing huts and for solid structures. 
The extract of T. sericea (roots) inhibited the enzyme α-glucosidase (IC50 = 92 μg mL-1) better 
than acarbose (IC50 = 131 μg mL-1) and inhibited HIV reverse transcriptase (IC50 = 43 μg mL-
1) more effectively than Adriamycin® (IC50 100 μg mL-1) (Tshikalange et al., 2008). It was 
also reported that the  acetone extract of T. sericea (bark) were active against multidrug-
resistant Mycobacterium tuberculosis with a MIC less than 100 μg mL-1 (Green et al., 2010). 
The aqueous, ethanol and chloroform extracts of seeds and roots showed activity at 1 μg mL-1 
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against Bacillus pumulis (van Vuuren, 2008). These assays were all performed on crude 
extracts. However, it is known the Terminalia species are rich in tannins (Fyhrquist et al., 
2014; Manosroi et al., 2013) and that tannins can give false-positive results in enzyme assays.  
4.1.5 Previous phytochemical investigations 
 Various phytochemical studies have been conducted on T. sericea and several bioactive 
compounds (mainly triterpenoids and flavonoids) were obtained from different parts of the 
plant. Table 4.1 presents a summary of the isolated compound in the plant and its activity. 
Table 4.1: Bioactive compounds isolated in T. sericea (Figure 4.3). 
 
Plant part Extract Activity of extract Compound 
Bark Acetone Hypoglycaemic and 
antioxidant  activities 
Catechin  (4.10) 
(Nkobole, 2009) 
Bark Acetone Hypoglycaemic and 
antioxidant  activities 
Epicatechin (4.11) 
(Nkobole, 2009) 
Bark Acetone Hypoglycaemic and 




Bark Acetone Hypoglycaemic and 
antioxidant  activities 
Gallocatechin  (4.13) 
(Nkobole, 2009) 
Bark Acetone Hypoglycaemic activity Lupeol (4.14) 
(Nkobole, 2009) 
Bark Acetone Hypoglycaemic activity Sericoside (4.15) 
(Nkobole, 2009) 
Bark Acetone Hypoglycaemic activity β-Sitosterol (4.16) 
 (Nkobole, 2009) 
Bark Acetone Hypoglycaemic activity β-Sitosterol 3-acetate   
(4.17) (Nkobole, 
2009) 
Root bark Ethanol - Arjungenin (4.18) 
(Joseph et al., 2007) 
Root bark Ethanol - Resveratrol 3-β- 
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rutinoside (4.19) 
(Joseph et al., 2007) 
Root bark Ethanol Responsible for the 
protective ability of wines 
against coronary heart 
disease 
Resveratrol glucoside 
(4.20)   
(Joseph et al., 2007)   
Root bark Ethanol - Stilbene glycoside 
(4.21) (Joseph et al., 
2007) 
Root bark Ethanol - Stigmasterol (4.22) 
(Joseph et al., 2007) 
Roots Ethyl acetate Antibacterial, antifungal, 
antimalarial and anti-HIV 
activities (Eldeen, 2008) 
 Anolignan A (4.23) 
 (Eldeen, 2008) 
 
Roots Ethyl acetate Antibacterial and anti-
inflammatory activities 
Anolignan B (4.24) 
(Eldeen et al., 2006) 
Roots Ethyl acetate activity against Gram-
positive and Gram-
negative bacteria 
Arjunic acid  (4.25) 
(Eldeen, 2008) 
 
Roots Ethyl acetate - Arjunglucoside 
(4.26) 
(Fyhrquist et al., 
2006) 
Roots Ethyl acetate Activity against Gram-
positive and Gram-
negative bacteria 
Termilignan B (4.27) 
(Eldeen, 2008) 
Roots - Hypoglycaemic activity 
(Musabayane et al., 2005) 
Oleanolic acid  (4.28) 
(Eldeen, 2008) 
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4.2 RESULTS AND DISCUSSION  
4.2.1 Isolation of sericic acid (4.29) 
The MeOH extract of T. sericea roots was assayed for antidiabetic activity (see Section 4.2.2). 
In the assay, antidiabetic activity was observed. A phytochemical analysis resulted in the 
isolation of one compound (4.29). The small amount of extract available did not allow us to 










The 1H NMR (Plate 5a) and 13C NMR (Plate 5b) spectra of 4.29 were consistent with an 
olean-12-ene type pentacyclic triterpene. In the 13C NMR spectrum of 4.29 29 resonances 
corresponding to six CH3 carbons, nine CH2, seven CH and seven quaternary carbons were 
observed. The spectrum also showed two olefinic C-atoms at δC 124.5 and δC 145.0. In the 
13C NMR spectrum, four oxygen-containing carbon atoms, three of which were methine 
carbons resonating at δC 85.9, 82.8 and 70.1 and one which was a methylene carbon 
resonating at δC 66.5. The 1H NMR spectrum of 4.29 showed six three-proton singlets at δH 
0.73, 0.92, 0.95, 0.98, 1.25, and 1.28, which can be assigned to six tertiary methyl groups, and 
one olefinic proton resonance at δH 5.49 (s, H-12).  1H, 13C correlations observed in the 
HMBC spectrum indicated that the A-ring is oxygenated at C-2 and C-3 as well as on one of 
the methyl groups on C-4. In Figure 4.4 some of the 1H,13C correlations observed in the 











Figure 4.4: Selected HMBC correlations of 4.29. 
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Based on the NMR data, the structure of 4.29 was assigned as sericic acid, a triterpenoid 
isolated from several Terminalia species. The NMR assignments correspond to those reported 
by Ponou et al. (Ponou et al., 2011). In the 13C NMR spectrum we did not observe a resonance 
for the carboxylic acid carbon, most likely because of a long relaxation time for this carbon. 
Sericic acid was first reported from T. sericea together with its glucosyl ester 4.15 
(Bombarde.E et al., 1974). Is known that 4.29 occurs in different species of Terminalia and 
was also isolated in members of other families (Hess and Monache, 1999). 
In the next section the effect of the crude MeOH extract of T. sericea roots on the glucose 
utilization of two cell line are described. Unfortunately we did not have enough material of 
4.29 to repeat the experiment with the pure compound. 
4.2.2 Antidiabetic activity and cytotoxicity of the methanol extract of T. sericea  
4.2.2.1 Cytotoxicity screening  
To evaluate the antidiabetic activity of the MeOH extract (roots) of T. sericea, the same 
experimental procedures as reported for H. colchicifolia were used. The first assay determined 
the viability of liver and muscle cell lines in the presence of the crude extract of T. sericea. 
The viability of a liver cell line (Chang) was determined by treating the cells with the extract 
at 12.5, 25 and 50 μg mL-1 and the viability was determined at 12, 24 and 48 h (Figure 4.5). A 
significant reduction in viability was observed at all three concentrations after 24 and 48 h. 
These results show that the T. sericea extract is toxic to this cell line.  
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Figure 4.5: Cell viability of liver cell line (Chang) treated with T. sericea extract at 
concentration of 12.5, 25 and 50 μg mL-1 after 12, 24 and 48 h. ٭ = p < 0.05 in comparison to 
control. 
The experiment was repeated with a muscle cell line (C2C12) and the results are shown in 
Figure 4.6. 
 
Figure 4.6: Cell viability of muscle cell line (C2C12) treated with T. sericea extract at 
concentrations of 12.5, 25 and 50 μg mL-1 after 12, 24 and 48 h. ٭ = p < 0.05 in comparison to 
control. 
 
It is clear that the viability of the muscle cells (C2C12) is affected to a lesser degree by the 
extract of T. sericea than the liver cells, but some cytotoxicity is still observed.  
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4.2.2.2 Glucose utilization when the cells are treated with the methanol extract of T. 
sericea 
The muscle cell line (C2C12) was treated with different concentrations of the extract. The 
results (Figure 4.7) showed that treatment with the extract resulted in significant reduction in 
the level of glucose in the medium. 
         
Figure 4.7: Effect of T. sericea concentration (12.5, 25 and 50 μg mL-1) on glucose utilization 
in muscle (C2C12) cell line after 12, 24 and 48 h. ٭ = p < 0.05 in comparison to control. 
 
The results of utilization of glucose in muscle cells (C2C12) when treated with concentrations 
of 12.5, 25 and 50 μg mL-1 of extract show that for the muscle cells, a significant reduction in 
the level of glucose in concentrations of 25-50 μg mL-1 was observed, while for a 
concentration 12.5 μg mL-1 the glucose level remains constant after 24 h. These results 
indicated that the extract increases the glucose utilization of the C2C12 muscle cell line and 
that the effect was dose dependent.  
The experiment was repeated with a liver cell line (Chang) and the results are shown in Figure 
4.8. 
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Figure 4.8: Effect of the T. sericea extract (12.5, 25 and 50 μgmL-1) on glucose utilization in 
liver cell line (Chang) after 12, 24 and 48 h. ٭ = p < 0.05 in comparison to control. 
 
For liver cells (Chang) the results of the glucose utilization when the cells are treated with the 
MeOH extract of T. sericea (roots) show that regardless of the concentration, there is a 
significant reduction of the level of glucose after 24 h. This is an indication that the extract 
caused a significant increase in the glucose utilization in both the C2C12 muscle cells and 
Chang liver cells which indicated that it has antidiabetic activity. 
4.3 CONCLUSION  
In the current phytochemical study, one known compound (4.29) was isolated from the 
methanol extract of T. sericea roots. 
The MeOH extract of T. sericea roots exhibited in vitro hypoglycaemic activity which 
validates the utilization of T. sericea roots to treat diabetes in traditional medicine. However, 
it can be concluded from the analysis of results that the MeOH extract of T. sericea roots also 
show some cytotoxicity toward both cell lines. 
This is the first study that reports in vitro antidiabetic activity for T. sericea roots. Previously 
Nkobole (2009) reported that the acetone extract T. sericea (stem bark) had inhibitory activity 
against α-amylase enzyme (90%) and α-glycosidase (97%) (Nkobole, 2009). 
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Future studies are needed in order to determine the mechanism by which the root extract of T. 
sericea has hypoglycaemic activity and to test the activity of the isolated compounds. 
 
4.4 EXPERIMENTAL 
4.4.1 Collection of plant material 
T. sericea roots were collected in Maputo National Reserve, Maputo Province, Mozambique. 
The plant was identified by Antonio Mapanga (botanist in Department of Biological Science 
at the University Eduardo Mondlane, Mozambique) and a voucher (T.S. 205) was deposited 
in the Herbarium of the Department of Biological Science at the University Eduardo 
Mondlane, Mozambique. The plant material was air-dried in the shade at room temperature 
for 2 weeks.  It was then ground with a mechanical mill, affording a mass of 103 g. 
The root powder (103 g) was extracted successively with DCM and MeOH, for 24 h each at 
room temperature. After each extraction, the solvent was filtered using Whatman® No 1 filter 
paper and concentrated under vacuum using a rotary evaporator. The extracts were then dried 
under high vacuum. The yields were 2.6 g for the DCM extract and 4.2 g for the MeOH 
extract. 
4.4.2 Extraction and isolation of sericic acid (4.29) 
The dry MeOH extract (2.5 g) was diluted with H2O and the dark solution was extracted with 
DCM and then with n-BuOH. Both extracts were evaporated under vacuum to dryness, to 
yield 135 mg and 636 mg for the DCM and n-BuOH extract, respectively (adapted from 
Bombarde et al., 1974). The BuOH extract was concentrated, diluted with diethyl ether and a 
brown solid collected. The BuOH extract was subjected to column chromatography with the 
mobile phase MeOH: EtOAc (1:19) to yield 2.1 mg of compound 29.4. 


























4.4.3 Physical properties of sericic acid (4.29) 
Sericic acid (4.29) was isolated as a white solid substance. 1H NMR (400 MHz, CD3OD): δH 
5.49 (1H, s, H-12); 4.03 (1H, d. J = 11.2 Hz, Ha-24); 3.80 (1H, ddd, J = 11.0, 9.5, 4.4 Hz, H-
2); 3.39 (1H, d, J = 11.2 Hz, Hb-24); 3.26 (1H, d, J = 4.0 Hz, H-19); 3.07 (1H, d, J = 4.0 Hz, 
H-18); 3.06 (1H, d, J = 9.5 Hz, H-3); 1.99-1.96 (2H, m, H-11); 1.93 (1H, dd, J = 12.0 Hz, 4.5, 
Heq-1); 1.80-1.74 (1H, m, Ha-7); 1.79-1.74 (1H, m, Ha-21); 1.75-1.67 (1H, m, H-9); 1.65-1.60 
(1H, m, Hb-7); 1.64-1.60 (1H, m, Ha-15); 1.64-1.59 (1H, m, Ha-6); 1.50-1.45 (1H, m, Ha-22); 
1.46-1.42 (1H, m, Hb-6); 1.34-1.30 (1H, m, Hb-22); 1.28 (3H, s, H-27); 1.25 (3H, s, H-23); 
1.02-0.98 (1H, m, Hb-21); 1.00-0.97 (1H, m, Hb-15); 0.98 (3H, s, H-25); 0.99 - 0.96 (1H, m, 
H-5); 0.95 (3H, s, H-30); 0.92 (3H, s, H-29), 0.90 (1H, dd, J = 12.0 and 10.9 Hz, Hax-1); 0.73 
(3H, s, H-26). 13C NMR (100 MHz, CD3OD): δC 145.0 (C-13); 124.3 (C-12); 85.9 (C-3); 82.8 
(C-19); 70.1 (C-2); 66.5 (C-24); 57.6 (C-5); 49.1 (C-9); 48.1 (C-1); 47.1 (C-17); 44.9 (C-18); 
44.3 (C-4); 43.0 (C-14); 41.2 (C-8); 39.1 (C-10); 35.9 (C-20); 34.4 (C-22); 33.9 (C-7); 29.9 
(C-15); 29.6 (C-21); 28.9 (C-29); 28.5 (C-16); 25.2 (C-30) and (C-11); 25.0 (C-27); 24.1 (C-
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CHAPTER 5: GENERAL CONCLUSIONS 
 
In most plants, the active compounds are secondary metabolites. These compounds  are 
responsible for protecting plants against microbial infections or infestations by pests 
(Doughari  and Rao, 2012; Sarker et al., 2006). Natural products isolated from plants and 
microorganisms have played a vital role as a source of lead compounds for the pharmaceutical 
industry.  
 
In this project, the phytochemical and antidiabetic activity of two medicinal plants from South 
Africa namely Hypoxis colchicifolia Bak (Hypoxidaceae) and Terminalia sericea Burch. 
(Combretaceae) were studied. 
H. colchicifolia (H. latifolia) is after H. hemerocallidea (African Potato) the second most 
important Hypoxis medicinal species with commercial value in South Africa. From the 
methanol extract of the corms four phenolic derivatives, hypoxoside, a mixture of 
dehydroxyhypoxoside A and B and bis-dehydroxyhypoxoside were isolated as well as an 
environmental impurity, bisphenol A diglycidyl ether. This is the first report on the isolation 
of dehydroxyhypoxoside B. The results showed that the MeOH extract of H. colchicifolia 
decreased the level of glucose and it has low toxicity in vitro. 
T. sericea is an important plant in traditional medicine and is in the top 50 most important 
African medicinal plants. From the methanol extract of the roots one known compound, 
sericic acid, was isolated. T. sericea exhibited in vitro hypoglycaemic activity, but also 
showed some cytotoxicity.  
 
These results validate the use of H. colchicifolia and T. sericea to treat diabetes in traditional 
medicine. Future studies are needed to determine the mechanism by which both plants present 
the hypoglycaemic activity. There are many plants used for the treatment of diabetes, but it is 
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APPENDIX:  NMR, IR, UV AND HR-MS SPECTRA OF THE 
ISOLATED COMPOUNDS 
Plate 1a:  1H NMR spectrum of hypoxoside (3.1) in CD3OD. 
Plate 1b:  13C NMR spectrum of hypoxoside (3.1) in CD3OD. 
Plate 1c:  COSY NMR spectrum of hypoxoside (3.1) in CD3OD. 
Plate 1d:  HSQC NMR spectrum of hypoxoside (3.1) in CD3OD. 
Plate 1e:  HMBC NMR spectrum of hypoxoside (3.1) in CD3OD. 
Plate 1f:  IR spectrum of hypoxoside (3.1). 
Plate 1g:  UV spectrum of hypoxoside (3.1) in MeOH. 
Plate 1h:  High-resolution mass spectrum of hypoxoside (3.1). 
Plate 2a:  1H NMR spectrum of dehydroxyhypoxoside A (3.14) and B (3.15) in CD3OD. 
Plate 2b:  13C NMR spectrum of dehydroxyhypoxoside A (3.14) and B (3.15) in CD3OD. 
Plate 2c:  COSY NMR spectrum of dehydroxyhypoxoside A (3.14) and B (3.15) in 
CD3OD. 
Plate 2d:  HSQC NMR spectrum of dehydroxyhypoxoside A (3.14) and B (3.15) in 
CD3OD. 
Plate 2e:  HMBC NMR spectrum of dehydroxyhypoxoside A (3.14) and B (3.15) in 
CD3OD. 
Plate 1f:  DEPT NMR spectrum of hypoxoside (3.1) in CD3OD 
Plate 2g:  IR spectrum of dehydroxyhypoxoside A (3.14) and B (3.15). 
Plate 2h:  UV spectrum of dehydroxyhypoxoside A (3.14) and B (3.15) in MeOH. 
78 | P a g e  
 
Plate 2i:  High-resolution mass spectrum of dehydroxyhypoxoside A (3.14) and B 
(3.15). 
Plate 3a:  1H NMR spectrum of bis-dehydroxyhypoxoside (3.16) in CD3OD. 
Plate 3b:  13C NMR spectrum of bis-dehydroxyhypoxoside (3.16) in CD3OD. 
Plate 3c:  COSY NMR spectrum of bis-dehydroxyhypoxoside (3.16) in CD3OD. 
Plate 3d:  HSQC NMR spectrum of bis-dehydroxyhypoxoside (3.16) in CD3OD. 
Plate 3e:  HMBC NMR spectrum of bis-dehydroxyhypoxoside (3.16) in CD3OD. 
Plate 2i:  DEPT NMR spectrum of dehydroxyhypoxoside A (3.14) and B (3.15) in 
CD3OD 
Plate 3g:  IR spectrum of bis-dehydroxyhypoxoside (3.16). 
Plate 3h:  UV spectrum of bis-dehydroxyhypoxoside (3.16) in MeOH. 
Plate 3i:  High-resolution mass spectrum of bis-dehydroxyhypoxoside (3.16). 
Plate 4a:  1H NMR spectrum of bisphenol A diglycidyl ether (3.17) in CDCl3. 
Plate 4b:  13C NMR spectrum of bisphenol A diglycidyl ether (3.17) in CDCl3. 
Plate 4c:  COSY NMR spectrum of bisphenol A diglycidyl ether (3.17) in CDCl3. 
Plate 4d:  HSQC NMR spectrum of bisphenol A diglycidyl ether (3.17) in CDCl3. 
Plate 4e:  HMBC NMR spectrum of bisphenol A diglycidyl ether (3.17) in CDCl3. 
Plate 4f:  High-resolution mass spectrum bisphenol A diglycidyl (3.17). 
Plate 5a:  1H NMR spectrum of sericic acid (4.29) in CD3OD. 
Plate 5b:  13C NMR spectrum of sericic acid (4.29) in CD3OD. 
Plate 5c:  HSQC NMR spectrum of sericic acid (4.29) in CD3OD. 
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Plate 5d:  HMBC NMR spectrum of sericic acid (4.29) in CD3OD. 
Plate 6a:  1H NMR spectrum of the fraction one (F1) in CD3OD 
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